{"id":"rucaparib","_fda":{"id":"473a8026-e822-2a9e-e063-6294a90a5c06","set_id":"0295d202-1cfe-7659-e063-6294a90a476e","openfda":{"unii":["41AX9SJ8KO"],"route":["ORAL"],"rxcui":["1862584","1862590","1862593","1862595","1921587","1921589"],"spl_id":["473a8026-e822-2a9e-e063-6294a90a5c06"],"brand_name":["Rubraca"],"spl_set_id":["0295d202-1cfe-7659-e063-6294a90a476e"],"package_ndc":["82154-0783-1","82154-0785-1","82154-0784-1"],"product_ndc":["82154-0783","82154-0785","82154-0784"],"generic_name":["RUCAPARIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["RUCAPARIB CAMSYLATE"],"manufacturer_name":["pharmaand GmbH"],"application_number":["NDA209115"],"is_original_packager":[true]},"version":"19","pregnancy":["8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, Rubraca can cause fetal harm when administered to pregnant women. There are no available data in pregnant women to inform the drug-associated risk. In an animal reproduction study, administration of rucaparib to pregnant rats during organogenesis resulted in embryo-fetal death at maternal exposures that were 0.04 times the AUC 0-24h in patients receiving the recommended dose of 600 mg twice daily [see Data] . Apprise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a dose range-finding embryo-fetal development study, pregnant rats received oral doses of 50, 150, 500, or 1000 mg/kg/day of rucaparib during the period of organogenesis. Post-implantation loss (100% early resorptions) was observed in all animals at doses greater than or equal to 50 mg/kg/day (with maternal systemic exposures approximately 0.04 times the human exposure at the recommended dose based on AUC 0-24h ).","Risk Summary Based on findings from animal studies and its mechanism of action, Rubraca can cause fetal harm when administered to pregnant women. There are no available data in pregnant women to inform the drug-associated risk. In an animal reproduction study, administration of rucaparib to pregnant rats during organogenesis resulted in embryo-fetal death at maternal exposures that were 0.04 times the AUC 0-24h in patients receiving the recommended dose of 600 mg twice daily [see Data] . Apprise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."],"description":["11 DESCRIPTION Rucaparib is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme. The chemical name is 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid salt. The chemical formula of rucaparib camsylate is C 19 H 18 FN 3 O•C 10 H 16 O 4 S and the relative molecular mass is 555.67 Daltons. The chemical structure of rucaparib camsylate is shown below: Rucaparib camsylate is a white to pale yellow powder; formulated into a tablet for oral use. Rucaparib shows pH-independent low solubility of approximately 1 mg/mL across the physiological pH range. Rubraca (rucaparib) tablets contain rucaparib camsylate as the active ingredient. Each 200 mg tablet contains 344 mg rucaparib camsylate equivalent to 200 mg rucaparib free base. Each 250 mg tablet contains 430 mg rucaparib camsylate equivalent to 250 mg rucaparib free base. Each 300 mg tablet contains 516 mg rucaparib camsylate equivalent to 300 mg rucaparib free base. The inactive ingredients in Rubraca tablets include: microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The cosmetic blue film coating for 200 mg tablets, cosmetic white film coating for 250 mg tablets, and cosmetic yellow film coating for 300 mg tablets is Opadry II containing polyvinyl alcohol, titanium dioxide, polyethylene glycol/macrogol, and talc. The coating is colorized as blue using brilliant blue aluminum lake and indigo carmine aluminum lake, or yellow using yellow iron oxide. 1"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Rubraca is available as 200 mg, 250 mg, and 300 mg tablets. 200 mg Tablets: Blue, round, and debossed with “C2” on one side Supplied in bottles of 60 tablets (NDC:82154-0783-1) 250 mg Tablets: White, diamond, and debossed with “C25” on one side Supplied in bottles of 60 tablets (NDC:82154-0784-1) 300 mg Tablets: Yellow, oval, and debossed with “C3” on one side Supplied in bottles of 60 tablets (NDC:82154-0785-1) Storage Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [ see USP Controlled Room Temperature ]."],"geriatric_use":["8.5 Geriatric Use Of the 937 patients with ovarian cancer who received Rubraca in clinical trials including ARIEL3, 41% were age 65 or older and 10% were 75 years or older. No major differences in safety were observed between younger and older patients with ovarian cancer. Of the 209 patients with mCRPC who received Rubraca in TRITON2, 77% were age 65 or older and 33% were 75 years or older. No major differences in safety were observed between younger and older patients with mCRPC."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Rubraca in pediatric patients have not been established."],"effective_time":"20251231","clinical_studies":["14 CLINICAL STUDIES 14.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer The efficacy of Rubraca was investigated in ARIEL3 ( NCT01968213 ), a double-blind, multicenter clinical trial in which 564 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in response to platinum-based chemotherapy were randomized (2:1) to receive Rubraca tablets 600 mg orally twice daily (n=375) or placebo (n=189). Treatment was continued until disease progression or unacceptable toxicity. All patients had achieved a response (complete or partial) to their most recent platinum-based chemotherapy. Randomization was stratified by best response to last platinum (complete or partial), time to progression following the penultimate platinum therapy (6 to ≤12 months and >12 months), and tumor biomarker status. Tumor tissue samples were tested using a clinical trial assay (CTA) (N=564) and an investigational Foundation Medicine tissue test (n=518). Of the samples evaluated with both tests, tumor BRCA (t BRCA ) mutant status was confirmed for 99% (177/178) of t BRCA -positive patients determined by the CTA. Blood samples for 94% (186/196) of the t BRCA patients were evaluated using a central blood germline BRCA test. Based on these results, 70% (130/186) of the t BRCA patients had a germline BRCA mutation and 30% (56/186) had a somatic BRCA mutation. The efficacy results are based on the t BRCA (germline or somatic) subgroup. The major efficacy outcome was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (v1.1). Overall survival (OS) was an additional outcome measure. Of the 564 enrolled patients, 196 patients (35%) had a t BRCA mutation. Among the patients who had a tBRCA mutation, the median age was 58 years (range: 42 to 81) for patients receiving Rubraca and 59 years (range: 36 to 84) for those on placebo; the majority were White (84%); and 100% had an ECOG performance status of 0 or 1. All patients had received at least two prior platinum-based chemotherapies (range: 2 to 5). A total of 33% of patients were in complete response (CR) to their most recent therapy. The progression-free interval to penultimate platinum was 6-12 months in 41% of patients and >12 months in 59%. Prior bevacizumab therapy was reported for 22% of patients who received Rubraca and 17% of patients who received placebo. Measurable disease was present at baseline in 32% of patients. ARIEL3 demonstrated a statistically significant improvement in PFS for patients randomized to Rubraca as compared with placebo in patients who had a t BRCA mutation. Results from a blinded independent radiology review were consistent. Efficacy results for patients with a t BRCA mutation are summarized in Table 8 and Figure 1 . Table 8. Efficacy Results in Patients with tBRCA-mutated Ovarian Cancer – ARIEL3 (Investigator Assessment) a a t BRCA includes all patients with a deleterious germline or somatic BRCA mutation, as determined by the CTA. Rubraca N=130 Placebo N=66 Progression Free Survival Number of events, n (%) 67 (52%) 56 (85%) Median in months (95% CI) 16.6 (13.4-22.9) 5.4 (3.4-6.7) HR (95% CI) 0.23 (0.16, 0.34) p-value < 0.0001 Figure 1 Kaplan-Meier Curves of Progression-Free Survival in ARIEL3 as Assessed by Investigator: t BRCA Group A final OS analysis was conducted after 130 events were observed. Exploratory OS results showed a HR of 0.83 (95% CI: 0.58, 1.19) in the t BRCA subgroup with a median OS of 45.9 months (95% CI: 37.7, 59.6) for patients treated with Rubraca and 47.8 months (95% CI: 43.2, 55.8) for patients on placebo. 2 14.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer TRITON3 The efficacy of RUBRACA was evaluated in TRITON3 ( NCT02975934 ), a randomized, open-label, multi-center trial that evaluated RUBRACA compared to an androgen receptor pathway inhibitor (ARPI; enzalutamide or abiraterone acetate) or docetaxel in patients with progressive BRCA or ATM mutated metastatic castrate-resistant prostate cancer (mCRPC). The trial enrolled 405 patients with mCRPC, of whom 302 had BRCA mutations. Patients were required to have progressed on treatment with one ARPI and could not have received prior chemotherapy in the castrate-resistant setting. Prior taxane chemotherapy for castration-sensitive disease was permitted. Patients were required to be surgically or medically castrated with a castrate level of serum testosterone at study entry. BRCA gene mutation status was determined prospectively testing tumor tissue or plasma using Foundation Medicine, Inc. assays or through local testing. Patients were randomized (2:1) to receive RUBRACA 600 mg twice daily (n=270) or ARPI (enzalutamide or abiraterone acetate; n=60) or docetaxel (n=75). Randomization was stratified by ECOG performance status (0 or 1), hepatic metastases (present or not), and type of mutation ( BRCA 1, BRCA 2, or ATM ). If patients were being treated with androgen deprivation therapy (ADT), therapy was continued throughout the study. Bone-targeted agents were allowed. Of the 302 patients with BRCA m disease, the median age was 69 years (range: 45 to 92 years); 75% were White, 5% Black, 1.3% Asian, 0.3% American Indian or Alaska Native, 1% multiple races, and 18% unknown; 1.7% were Hispanic/Latino; and baseline ECOG performance status (PS) was 0 (49%) or 1 (51%). Forty percent of patients had bone-only disease; 32% had visceral disease. In the mCSPC setting, 23% of patients had received docetaxel. Among those with BRCA m disease, 40 patients had BRCA 1 mutations, and 262 patients had BRCA 2 mutations. The major efficacy outcome measure was radiographic progression-free survival (rPFS) as determined by independent radiology review (IRR) using RECIST version 1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteria. Additional efficacy outcome measures included overall survival (OS) and IRR-assessed objective response rate (ORR). TRITON3 demonstrated a statistically significant improvement in IRR-assessed rPFS for RUBRACA compared to ARPI or docetaxel in patients with BRCA m and in the overall population. In an exploratory analysis in the subgroup of 103 (25%) patients with ATM mutations, the rPFS hazard ratio was 0.95 (95% CI: 0.59, 1.52) and the OS hazard ratio was 1.21 (95% CI: 0.77, 1.90), indicating that the improvement in the overall population was primarily attributed to the results seen in the subgroup of patients with BRCA m. Of patients with BRCA m who were randomized to receive ARPI or docetaxel (n=101), 52% crossed over to receive RUBRACA after disease progression. Efficacy results of the BRCA m population in TRITON3 are provided in Table 9, Figure 2 and Figure 3. Table 9. Efficacy Results from the BRCAm Subgroup of the TRITON3 Study Endpoint Rubraca N=201 f ARPI or Docetaxel N=101 f Radiographic Progression Free Survival a Number of events, n (%) 115 (57%) 67 (66%) Median in months (95% CI) 11.2 (9.2-13.8) 6.4 (5.4-8.3) Hazard ratiob (95% CI) 0.50 (0.36, 0.69) p-value c < 0.0001 Overall Survival d Number of events, n (%) 152 (76%) 74 (73%) Median in months (95% CI) 23.2 (19.1, 25.2) 21.2 (18.0, 23.1) Hazard ratio b (95% CI) 0.91 (0.68, 1.20) p-value c NS Confirmed Overall Response Rate a,e N=82 N=41 Overall response rate (95% CI) 45.1 (34.1, 56.5) 17.1 (7.2, 32.1) Number of complete responses, n (%) 10 (12.2) 2 (4.9) Number of partial responses, n (%) 27 (32.9) 5 (12.2) NS=Not significant a Based on IRR assessment. b Cox proportional hazards model stratified by ECOG Status (0 or 1) and type of mutation ( BRCA 1 or BRCA 2). c P-value based on the stratified log-rank test d Based on pre-specified final analysis. e Based on patients with measurable disease at baseline per IRR assessment. Responses are based on soft tissue and bone lesion assessment. f Based on the BRCA mutation status used at the randomization. This excludes one patient with a reported ATM mutation at randomization but found to have a BRCA2 mutation based on the verified source. Figure 2 Kaplan-Meier Curves of rPFS from the BRCAm Subgroup of the TRITON3 Study (IRR-assessed) Figure 3 Kaplan-Meier Curves of Final OS from the BRCAm Subgroup of the TRITON3 Study Exploratory subgroup analysis of rPFS and OS for patients with BRCA1m and BRCA2m (including one patient with a BRCA2 mutation mischaracterized as having an ATM mutation at randomization) were performed. The rPFS and OS hazard ratios were 1.01 (95% CI: 0.48, 2.13) and 0.96 (95% CI: 0.46, 2.00) respectively in the subgroup with BRCA1 mutations (n=40) and 0.46 (95% CI: 0.33, 0.65) and 0.92 (95% CI: 0.68, 1.24) respectively in the subgroup with BRCA2 mutations (n=263). TRITON2 The efficacy of Rubraca was investigated in TRITON2 ( NCT02952534 ), an ongoing multi-center, single arm clinical trial in patients with BRCA -mutated mCRPC who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy. There were 115 patients with either germline or somatic BRCA mutations enrolled in TRITON2, of whom 62 patients had measurable disease at baseline by independent radiology review (IRR). Patients received Rubraca 600 mg orally twice daily until disease progression or unacceptable toxicity. Patients also received concomitant GnRH analog or had prior bilateral orchiectomy. Objective response rate (ORR) and duration of response (DOR) were assessed in patients with measurable disease by blinded IRR and by the investigator according to modified RECIST v1.1/ Prostate Cancer Working Group 3 (PCWG3) criteria. For the 62 patients with measurable disease at baseline, the median age was 73 years (range 52 to 88); the majority were White (73%) and 10% were Black; and 98% of patients had an ECOG performance status of 0 or 1. All patients had received at least one prior androgen receptor-directed therapy, 34% had received 2 prior androgen receptor-directed therapies and 2% had received 3 prior androgen receptor-directed therapies, and all patients also received prior taxane chemotherapy. Eighteen percent of patients had lung and 21% had liver metastases at baseline. Twenty-four percent had metastases to lymph nodes alone. Forty percent had 10 or more bone lesions at baseline. All 62 patients had a deleterious somatic or germline BRCA mutation detected from either central plasma (26%), central tissue (32%), or local (42%) testing. Of the 62 patients, 66% had a somatic BRCA mutation, 34% had a germline BRCA mutation, 85% had a BRCA2 mutation, and 15% had a BRCA1 mutation. The major efficacy outcomes of the study were confirmed ORR by IRR using modified RECIST v1.1/PCWG3 criteria and DOR. Efficacy results of TRITON2 are provided in Table 10. The ORR by IRR was similar in patients with germline versus somatic BRCA mutation. Table 10. Efficacy Results in Patients with BRCA-mutated mCRPC - TRITON2 (IRR-assessed) NE = not evaluable a Defined per modified RECIST v1.1 criteria and with no confirmed bone progression per PCWG3. b The range for the DOR was 1.7-24+ months. Fifteen of the 27 (56%) patients with a confirmed objective response had a DOR of ≥6 months. Rubraca (N = 62) Confirmed Objective Response Rate (95% CI) a 44% (31, 57) Median DOR in months (95% CI) b NE (6.4, NE) 5 4","14.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer The efficacy of Rubraca was investigated in ARIEL3 ( NCT01968213 ), a double-blind, multicenter clinical trial in which 564 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in response to platinum-based chemotherapy were randomized (2:1) to receive Rubraca tablets 600 mg orally twice daily (n=375) or placebo (n=189). Treatment was continued until disease progression or unacceptable toxicity. All patients had achieved a response (complete or partial) to their most recent platinum-based chemotherapy. Randomization was stratified by best response to last platinum (complete or partial), time to progression following the penultimate platinum therapy (6 to ≤12 months and >12 months), and tumor biomarker status. Tumor tissue samples were tested using a clinical trial assay (CTA) (N=564) and an investigational Foundation Medicine tissue test (n=518). Of the samples evaluated with both tests, tumor BRCA (t BRCA ) mutant status was confirmed for 99% (177/178) of t BRCA -positive patients determined by the CTA. Blood samples for 94% (186/196) of the t BRCA patients were evaluated using a central blood germline BRCA test. Based on these results, 70% (130/186) of the t BRCA patients had a germline BRCA mutation and 30% (56/186) had a somatic BRCA mutation. The efficacy results are based on the t BRCA (germline or somatic) subgroup. The major efficacy outcome was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (v1.1). Overall survival (OS) was an additional outcome measure. Of the 564 enrolled patients, 196 patients (35%) had a t BRCA mutation. Among the patients who had a tBRCA mutation, the median age was 58 years (range: 42 to 81) for patients receiving Rubraca and 59 years (range: 36 to 84) for those on placebo; the majority were White (84%); and 100% had an ECOG performance status of 0 or 1. All patients had received at least two prior platinum-based chemotherapies (range: 2 to 5). A total of 33% of patients were in complete response (CR) to their most recent therapy. The progression-free interval to penultimate platinum was 6-12 months in 41% of patients and >12 months in 59%. Prior bevacizumab therapy was reported for 22% of patients who received Rubraca and 17% of patients who received placebo. Measurable disease was present at baseline in 32% of patients. ARIEL3 demonstrated a statistically significant improvement in PFS for patients randomized to Rubraca as compared with placebo in patients who had a t BRCA mutation. Results from a blinded independent radiology review were consistent. Efficacy results for patients with a t BRCA mutation are summarized in Table 8 and Figure 1 . Table 8. Efficacy Results in Patients with tBRCA-mutated Ovarian Cancer – ARIEL3 (Investigator Assessment) a a t BRCA includes all patients with a deleterious germline or somatic BRCA mutation, as determined by the CTA. Rubraca N=130 Placebo N=66 Progression Free Survival Number of events, n (%) 67 (52%) 56 (85%) Median in months (95% CI) 16.6 (13.4-22.9) 5.4 (3.4-6.7) HR (95% CI) 0.23 (0.16, 0.34) p-value < 0.0001 Figure 1 Kaplan-Meier Curves of Progression-Free Survival in ARIEL3 as Assessed by Investigator: t BRCA Group A final OS analysis was conducted after 130 events were observed. Exploratory OS results showed a HR of 0.83 (95% CI: 0.58, 1.19) in the t BRCA subgroup with a median OS of 45.9 months (95% CI: 37.7, 59.6) for patients treated with Rubraca and 47.8 months (95% CI: 43.2, 55.8) for patients on placebo. 2","14.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer TRITON3 The efficacy of RUBRACA was evaluated in TRITON3 ( NCT02975934 ), a randomized, open-label, multi-center trial that evaluated RUBRACA compared to an androgen receptor pathway inhibitor (ARPI; enzalutamide or abiraterone acetate) or docetaxel in patients with progressive BRCA or ATM mutated metastatic castrate-resistant prostate cancer (mCRPC). The trial enrolled 405 patients with mCRPC, of whom 302 had BRCA mutations. Patients were required to have progressed on treatment with one ARPI and could not have received prior chemotherapy in the castrate-resistant setting. Prior taxane chemotherapy for castration-sensitive disease was permitted. Patients were required to be surgically or medically castrated with a castrate level of serum testosterone at study entry. BRCA gene mutation status was determined prospectively testing tumor tissue or plasma using Foundation Medicine, Inc. assays or through local testing. Patients were randomized (2:1) to receive RUBRACA 600 mg twice daily (n=270) or ARPI (enzalutamide or abiraterone acetate; n=60) or docetaxel (n=75). Randomization was stratified by ECOG performance status (0 or 1), hepatic metastases (present or not), and type of mutation ( BRCA 1, BRCA 2, or ATM ). If patients were being treated with androgen deprivation therapy (ADT), therapy was continued throughout the study. Bone-targeted agents were allowed. Of the 302 patients with BRCA m disease, the median age was 69 years (range: 45 to 92 years); 75% were White, 5% Black, 1.3% Asian, 0.3% American Indian or Alaska Native, 1% multiple races, and 18% unknown; 1.7% were Hispanic/Latino; and baseline ECOG performance status (PS) was 0 (49%) or 1 (51%). Forty percent of patients had bone-only disease; 32% had visceral disease. In the mCSPC setting, 23% of patients had received docetaxel. Among those with BRCA m disease, 40 patients had BRCA 1 mutations, and 262 patients had BRCA 2 mutations. The major efficacy outcome measure was radiographic progression-free survival (rPFS) as determined by independent radiology review (IRR) using RECIST version 1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteria. Additional efficacy outcome measures included overall survival (OS) and IRR-assessed objective response rate (ORR). TRITON3 demonstrated a statistically significant improvement in IRR-assessed rPFS for RUBRACA compared to ARPI or docetaxel in patients with BRCA m and in the overall population. In an exploratory analysis in the subgroup of 103 (25%) patients with ATM mutations, the rPFS hazard ratio was 0.95 (95% CI: 0.59, 1.52) and the OS hazard ratio was 1.21 (95% CI: 0.77, 1.90), indicating that the improvement in the overall population was primarily attributed to the results seen in the subgroup of patients with BRCA m. Of patients with BRCA m who were randomized to receive ARPI or docetaxel (n=101), 52% crossed over to receive RUBRACA after disease progression. Efficacy results of the BRCA m population in TRITON3 are provided in Table 9, Figure 2 and Figure 3. Table 9. Efficacy Results from the BRCAm Subgroup of the TRITON3 Study Endpoint Rubraca N=201 f ARPI or Docetaxel N=101 f Radiographic Progression Free Survival a Number of events, n (%) 115 (57%) 67 (66%) Median in months (95% CI) 11.2 (9.2-13.8) 6.4 (5.4-8.3) Hazard ratiob (95% CI) 0.50 (0.36, 0.69) p-value c < 0.0001 Overall Survival d Number of events, n (%) 152 (76%) 74 (73%) Median in months (95% CI) 23.2 (19.1, 25.2) 21.2 (18.0, 23.1) Hazard ratio b (95% CI) 0.91 (0.68, 1.20) p-value c NS Confirmed Overall Response Rate a,e N=82 N=41 Overall response rate (95% CI) 45.1 (34.1, 56.5) 17.1 (7.2, 32.1) Number of complete responses, n (%) 10 (12.2) 2 (4.9) Number of partial responses, n (%) 27 (32.9) 5 (12.2) NS=Not significant a Based on IRR assessment. b Cox proportional hazards model stratified by ECOG Status (0 or 1) and type of mutation ( BRCA 1 or BRCA 2). c P-value based on the stratified log-rank test d Based on pre-specified final analysis. e Based on patients with measurable disease at baseline per IRR assessment. Responses are based on soft tissue and bone lesion assessment. f Based on the BRCA mutation status used at the randomization. This excludes one patient with a reported ATM mutation at randomization but found to have a BRCA2 mutation based on the verified source. Figure 2 Kaplan-Meier Curves of rPFS from the BRCAm Subgroup of the TRITON3 Study (IRR-assessed) Figure 3 Kaplan-Meier Curves of Final OS from the BRCAm Subgroup of the TRITON3 Study Exploratory subgroup analysis of rPFS and OS for patients with BRCA1m and BRCA2m (including one patient with a BRCA2 mutation mischaracterized as having an ATM mutation at randomization) were performed. The rPFS and OS hazard ratios were 1.01 (95% CI: 0.48, 2.13) and 0.96 (95% CI: 0.46, 2.00) respectively in the subgroup with BRCA1 mutations (n=40) and 0.46 (95% CI: 0.33, 0.65) and 0.92 (95% CI: 0.68, 1.24) respectively in the subgroup with BRCA2 mutations (n=263). TRITON2 The efficacy of Rubraca was investigated in TRITON2 ( NCT02952534 ), an ongoing multi-center, single arm clinical trial in patients with BRCA -mutated mCRPC who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy. There were 115 patients with either germline or somatic BRCA mutations enrolled in TRITON2, of whom 62 patients had measurable disease at baseline by independent radiology review (IRR). Patients received Rubraca 600 mg orally twice daily until disease progression or unacceptable toxicity. Patients also received concomitant GnRH analog or had prior bilateral orchiectomy. Objective response rate (ORR) and duration of response (DOR) were assessed in patients with measurable disease by blinded IRR and by the investigator according to modified RECIST v1.1/ Prostate Cancer Working Group 3 (PCWG3) criteria. For the 62 patients with measurable disease at baseline, the median age was 73 years (range 52 to 88); the majority were White (73%) and 10% were Black; and 98% of patients had an ECOG performance status of 0 or 1. All patients had received at least one prior androgen receptor-directed therapy, 34% had received 2 prior androgen receptor-directed therapies and 2% had received 3 prior androgen receptor-directed therapies, and all patients also received prior taxane chemotherapy. Eighteen percent of patients had lung and 21% had liver metastases at baseline. Twenty-four percent had metastases to lymph nodes alone. Forty percent had 10 or more bone lesions at baseline. All 62 patients had a deleterious somatic or germline BRCA mutation detected from either central plasma (26%), central tissue (32%), or local (42%) testing. Of the 62 patients, 66% had a somatic BRCA mutation, 34% had a germline BRCA mutation, 85% had a BRCA2 mutation, and 15% had a BRCA1 mutation. The major efficacy outcomes of the study were confirmed ORR by IRR using modified RECIST v1.1/PCWG3 criteria and DOR. Efficacy results of TRITON2 are provided in Table 10. The ORR by IRR was similar in patients with germline versus somatic BRCA mutation. Table 10. Efficacy Results in Patients with BRCA-mutated mCRPC - TRITON2 (IRR-assessed) NE = not evaluable a Defined per modified RECIST v1.1 criteria and with no confirmed bone progression per PCWG3. b The range for the DOR was 1.7-24+ months. Fifteen of the 27 (56%) patients with a confirmed objective response had a DOR of ≥6 months. Rubraca (N = 62) Confirmed Objective Response Rate (95% CI) a 44% (31, 57) Median DOR in months (95% CI) b NE (6.4, NE) 5 4"],"pharmacodynamics":["12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of rucaparib has not fully been characterized. Cardiac Electrophysiology A positive concentration-QTc relationship was observed in patients who were administered continuous dosages of Rubraca ranging from 40 mg once daily (0.03 times the approved recommended dosage) to 840 mg twice daily (1.4 times the approved recommended dosage). The mean (90% confidence interval [CI]) QTcF increase from baseline at steady state of Rubraca 600 mg twice daily was 14.9 msec (11.1, 18.7 msec)."],"pharmacokinetics":["12.3 Pharmacokinetics The AUC and C max of rucaparib demonstrated linear pharmacokinetics over a dose range from 240 mg to 840 mg twice daily (0.4 times to 1.4 times the approved recommended dosage). The mean (coefficient of variation [CV]) steady-state rucaparib C max is 1,940 ng/mL (54%) and AUC 0-12h is 16,900 h×ng/mL (54%) at the approved recommended dosage. The mean AUC accumulation ratio is 3.5 to 6.2 fold. Absorption The median T max (min, max) at the steady state is 1.9 hours (0, 5.98) at the approved recommended dosage. The mean (min, max) absolute bioavailability is 36% (30%, 45%). Effect of Food Following a high-fat meal (approximately 800-1000 calories, including approximately 250 calories from carbohydrates, approximately 500-600 calories from fat, approximately 150 calories from protein), the C max was increased by 20%, AUC 0-24h was increased by 38%, and the T max was delayed by 2.5 hours, as compared to fasted conditions [see Dosage and Administration ( 2.2 )] . Distribution The mean apparent volume of distribution is 2300 L (21%). Rucaparib is 70% bound to human plasma proteins in vitro. Rucaparib preferentially distributed to red blood cells with a blood-to-plasma concentration ratio of 1.8. Elimination The mean apparent total clearance at steady state is 44.2 L/h (45%) and the mean terminal elimination half-life is 26 (39%) hours. Metabolism In vitro, rucaparib is primarily metabolized by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. In addition to CYP-based oxidation, rucaparib also undergoes N-demethylation, N-methylation, and glucuronidation. Excretion Following a single oral dose of radiolabeled rucaparib, unchanged rucaparib accounted for 64% of the radioactivity. Rucaparib accounted for 45% and 95% of radioactivity in urine and feces, respectively. Specific Populations Age (20 to 86 years), race (White, Black, and Asian), sex, body weight (41 to 171 kg), mild to moderate renal impairment (CLcr ≥ 30 mL/min), mild hepatic impairment (total bilirubin < ULN and AST > ULN or total bilirubin 1 to 1.5 x ULN and any AST), and CYP2D6 or CYP1A2 genotype polymorphisms did not have a clinically meaningful effect on the pharmacokinetics of rucaparib. The effect of severe renal impairment (CLcr 15 to 29 mL/min), end-stage renal disease (CLcr < 15 mL/min), or severe hepatic impairment (total bilirubin > 3 x ULN and any AST) has not been studied. Hepatic Impairment Moderate hepatic impairment (total bilirubin > 1.5 to 3 x ULN and any AST) increased rucaparib AUC by 45%, but had no effect on C max compared to patients with normal hepatic function. Drug Interaction Studies Clinical Studies and Model-Informed Approaches Effect of Other Drugs on Rucaparib Concomitant administration of Rubraca with a proton pump inhibitor had no clinically meaningful effect on steady-state concentrations of rucaparib. Effect of Rucaparib on Other Drugs Concomitant administration of Rubraca with rosuvastatin (BCRP substrate) had no clinically meaningful effect on the concentrations of rosuvastatin. Coadministration of Rubraca with the following substrates increased the C max of each coadministered substrate by ≤ 1.1-fold and increased the AUC of each substrate as follows: Caffeine (CYP1A2): by 2.6-fold Midazolam (CYP3A4): by 1.4-fold Warfarin (CYP2C9): by 1.5-fold Omeprazole (CYP2C19): by 1.6-fold Digoxin (P-glycoprotein): by 1.2-fold Concomitant administration of Rubraca with an oral contraceptive containing ethinylestradiol and levonorgestrel (CYP3A substrates): increased ethinylestradiol AUC by 1.4-fold and levonorgestrel AUC by 1.6-fold, but did not have a clinically meaningful effect on their C max . In Vitro Studies Cytochrome P450 (CYP) Enzymes : Rucaparib inhibited CYP2C8 and CYP2D6 and induced CYP1A2. UDP-glucuronosyltransferase (UGT) Enzymes : Rucaparib inhibited UGT1A1. Transporter Systems : Rucaparib is a substrate of P-gp and BCRP. Rucaparib is not a substrate of OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. Rucaparib inhibited OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, OCT1, OCT2, and MRP4. Rucaparib did not inhibit MRP2, MRP3, or BSEP."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions ( 5.1 )]. Most common adverse reactions (≥10%) among patients with ovarian cancer were nausea, fatigue (including asthenia), anemia, ALT/AST increased, vomiting, diarrhea, decreased appetite, thrombocytopenia, dysgeusia, neutropenia, blood creatinine increased, dyspnea, dizziness, dyspepsia, photosensitivity reaction, and leukopenia. ( 6.1 ) Most common adverse reactions (≥10%) among patients with BRCA -mutated mCRPC were fatigue/asthenia, musculoskeletal pain, nausea, anemia, decreased appetite, increased ALT/AST, constipation, diarrhea, vomiting, thrombocytopenia, dyspnea, increased blood creatinine, edema, dizziness, weight decreased, abdominal pain, dysgeusia, rash, neuropathy peripheral, urinary tract infection, cough, headache, hemorrhage, neutropenia, and photosensitivity reaction. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact pharmaand agent at 1-800-506-8501 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population for patients with ovarian and prostate cancer in the WARNINGS AND PRECAUTIONS section reflect exposure to RUBRACA at 600 mg orally twice daily in 2141 patients treated on clinical trials including ARIEL3, TRITON2, and TRITON3. In ARIEL3 among the patients who received RUBRACA, 57% of patients were exposed for 6 months or longer and 33% were exposed for greater than one year. In TRITON3 among the patients with BRCA-mutated mCRPC who received RUBRACA, 66% were exposed for 6 months or longer and 34% were exposed for greater than one year. In the pooled safety population for patients with ovarian cancer, the most common adverse reactions in ≥ 10% of patients were nausea (68%), asthenia/fatigue (65%), anemia/hemoglobin decreased (45%), AST/ALT increased (39%), vomiting (36%), diarrhea (29%), decreased appetite (27%), thrombocytopenia/platelet count decreased (25%), dysgeusia (24%), neutropenia/neutrophil count decreased (21%), blood creatinine increased (17%), dyspnea (16%), dizziness (14%), dyspepsia (11%), photosensitivity reaction (10%), and leukopenia/white blood cell count decreased (10%). In the pooled safety population for patients with BRCA -mutated mCRPC (N=373) from TRITON2 and TRITON3, the most common adverse reactions in ≥ 10% of patients were fatigue/asthenia (61%), musculoskeletal pain (52%), nausea (52%), anemia/decreased hemoglobin (49%), decreased appetite (35%), increased ALT/AST (31%), constipation (30%), diarrhea (27%), vomiting (26%), thrombocytopenia/decreased platelet count (21%), dyspnea (20%), increased blood creatinine (19%), edema (19%), dizziness (19%), weight decreased (16%), abdominal pain (15%), dysgeusia (15%), rash (13%), neuropathy peripheral (13%), urinary tract infection (13%), cough (12%), headache (12%), hemorrhage (12%), neutropenia/decreased neutrophil count (12%), and photosensitivity reaction (10%). Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer The safety of RUBRACA for the maintenance treatment of patients with BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer was investigated in ARIEL3, a randomized (2:1), double-blind, placebo-controlled study in which 195 patients with a deleterious BRC A mutation received either RUBRACA 600 mg orally twice daily (n=129) or placebo (n=66) until disease progression or unacceptable toxicity. The median duration of study treatment was 13.6 months (range: < 1 month to 39 months) for patients who received RUBRACA and 5.5 months for patients who received placebo. Dose interruptions due to an adverse reaction of any grade occurred in 67% of patients receiving RUBRACA and 14% of those receiving placebo; dose reductions due to an adverse reaction occurred in 57% of RUBRACA patients and 6% of placebo patients. The most frequent adverse reactions leading to dose interruption or dose reduction of RUBRACA were thrombocytopenia (25%), anemia (19%), ALT/AST increased (16%), fatigue/asthenia (14%), and nausea (10%). Discontinuation due to adverse reactions occurred in 15% of RUBRACA patients and 5% of placebo patients. Specific adverse reactions that most frequently led to discontinuation in patients treated with RUBRACA were thrombocytopenia (4%), nausea (3%), and anemia (2%). Table 2 describes the adverse reactions occurring in ≥20% of patients; while Table 3 describes the laboratory abnormalities occurring in ≥25% of patients occurring in ARIEL3. Table 2. Adverse Reactions in ≥ 20% of Patients with BRCA-mutated Ovarian Cancer in ARIEL3 a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) b Consists of grouped related terms that reflect the medical concept of the adverse reaction Adverse reactions RUBRACA N=129 Placebo N=66 Grades 1-4 a % Grades 3-4 % Grades 1-4 a % Grades 3-4 % Gastrointestinal Disorders Nausea 79 2 29 0 Abdominal pain/distention b 48 3 49 2 Constipation 39 4 36 2 Vomiting 37 4 14 0 Diarrhea 34 2 18 0 Stomatitis b 28 0.8 12 0 General Disorders and Administration Site Conditions Fatigue/asthenia 74 9 52 5 Skin and Subcutaneous Tissue Disorders Rash b 45 0 23 0 Nervous System Disorders Dysgeusia 33 0 6 0 Headache 22 0 15 2 Investigations ALT/AST elevation 33 16 3 0 Blood and Lymphatic System Disorders Anemia 41 26 6 0 Thrombocytopenia 35 6 3 0 Neutropenia 22 8 6 0 Respiratory, Thoracic, and Mediastinal Disorders Nasopharyngitis/Upper respiratory tract infection b 29 0 20 2 Metabolism and Nutrition Disorders Decreased appetite 23 2 14 0 Adverse reactions occurring < 20% of patients treated with RUBRACA include insomnia (19%), dyspnea (17%), dizziness (15%), pyrexia (15%), dyspepsia (12%), peripheral edema (12%), and depression (11%). Table 3. Laboratory Abnormalities in ≥ 25% of Patients with BRCA-mutated Ovarian Cancer in ARIEL3 a Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. b NCI CTCAE version 4.03. Laboratory Parameter a RUBRACA N=129 Placebo N=66 Grades 1-4 b % Grades 3-4 % Grades 1-4 b % Grades 3-4 % Chemistry Increase in creatinine 96 0 89 0 Increase in ALT 67 11 6 0 Increase in AST 59 1 6 0 Increase in cholesterol 39 3 20 0 Increase in Alkaline Phosphatase 39 0 3 0 Hematology Decrease in hemoglobin 61 18 14 2 Decrease in platelets 47 2 8 0 Decrease in leukocytes 39 3 23 0 Decrease in neutrophils 38 6 18 2 Decrease in lymphocytes 33 7 14 2 Treatment of BRCA-mutated mCRPC after Androgen Receptor-directed Therapy TRITON3 The safety of RUBRACA monotherapy was evaluated in patients with BRCA-mutated mCRPC who had progressed following prior treatment with androgen receptor-directed therapy and who had not received treatment with taxane-based chemotherapy in the castration-resistant setting. [see Clinical Studies ( 14.2 )]. TRITON3 was a randomized, open-label, multi-center study, in which 298 patients with a deleterious BRCA mutation received either RUBRACA 600 mg twice daily (n=201) or physicians choice (n=97) of abiraterone acetate or enzalutamide, or docetaxel until disease progression, unacceptable toxicity, or up to 10 cycles for docetaxel. Among the patients who received RUBRACA, 66% were exposed for 6 months or longer and 34% were exposed for greater than one year. Serious adverse reactions occurred in 27% of patients receiving RUBRACA. Serious adverse reactions in ≥2% of patients included anemia (4%), pneumonia (4%), urinary tract infection (3%), acute kidney injury (3%), myocardial ischemia/infarction (2%), and pulmonary embolism (2%). Fatal adverse reactions occurred in 1.5% of patients treated with RUBRACA, including cardiac failure, myocardial ischemia, and sepsis (1 patient each). Permanent discontinuation due to adverse reactions occurred in 14% of patients treated with RUBRACA. Adverse reactions which resulted in permanent discontinuation of RUBRACA in ≥2% of patients included anemia (6%), fatigue/asthenia (3%), thrombocytopenia/platelet count decreased (3%), and nausea (2%). Dosage interruptions of RUBRACA due to adverse reactions occurred in 53% of patients. Adverse reactions which required dosage interruption in ≥5% of patients included anemia (24%), fatigue/asthenia (10%), nausea (8%), and increase in ALT (5%). Dose reductions of RUBRACA due to an adverse reaction occurred in 36% of patients. Adverse reactions which required dose reduction in ≥5% of patients included anemia (16%) and fatigue/asthenia (8%). The most common adverse reactions (≥10%) in patients who received RUBRACA were fatigue/asthenia, musculoskeletal pain, nausea, decreased appetite, diarrhea, constipation, vomiting, dyspnea, dysgeusia, edema, abdominal pain, dizziness, weight decreased, rash, headache, peripheral neuropathy, photosensitivity reaction, and urinary tract infection. The most common select laboratory abnormalities (≥25%) that worsened from baseline in patients who received RUBRACA were increased ALT, decreased neutrophils, decreased phosphate, decreased hemoglobin, increased AST, increased creatinine, increased glucose, decreased lymphocytes, decreased sodium, decreased platelets, increased calcium. Tables 4 and 5 summarize the adverse reactions and laboratory abnormalities, respectively, in patients with BRCA- mutated mCRPC in TRITON3. Table 4. Adverse Reactions in ≥ 10% of Patients with BRCA-mutated mCRPC in TRITON3 a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0) b Includes multiple related terms Adverse Reaction RUBRACA N=201 ARPI or Docetaxel N=97 Grades 1-4 a (%) Grades 3-4 (%) Grades 1-4 a (%) Grades 3-4 (%) General disorders and administration site conditions Fatigue/Asthenia 61 7 65 10 Edema b 18 0 20 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain b 53 7 57 8 Gastrointestinal disorders Nausea 51 2 22 1 Diarrhea 31 2 29 1 Constipation 31 2 17 1 Vomiting 25 1 10 1 Abdominal pain b 17 1 10 1 Metabolism and nutrition disorders Decreased appetite 34 1 20 2 Respiratory, thoracic and mediastinal disorders Dyspnea b 19 1 13 1 Nervous system disorders Dysgeusia b 18 0 12 0 Dizziness b 16 1 9 0 Headache b 12 0 9 0 Peripheral neuropathy b 12 1 26 1 Investigations Weight decreased 16 1 13 0 Skin and subcutaneous tissue disorders Rash b 13 1 6 0 Photosensitivity reaction b 12 1 0 0 Infections and infestations Urinary tract infection b 10 3 4 1 Clinically relevant adverse reactions occurring in <10% of patients treated with RUBRACA include cough, hemorrhage, fall, hypertension, dyspepsia, pruritus, pyrexia, stomatitis, venous thromboembolism, arrhythmia, hypersensitivity, and febrile neutropenia. Table 5. Laboratory Abnormalities in ≥ 25% of Patients with BRCA-mutated mCRPC in TRITON3 a Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available for 192 to 201 patients in the RUBRACA Arm and 94 to 97 patients in the ARPI or Docetaxel Arm. b NCI CTCAE version 5.0; decrease in phosphate is graded using NCI CTACE Version 4.03 Laboratory Parameter Rubraca N=201 a ARPI or Docetaxel N=97 a Grades 1-4 b (%) Grades 3-4 (%) Grades 1-4 b (%) Grades 3-4 (%) Chemistry Increase in ALT 68 4 8 0 Decrease in phosphate 64 8 45 5 Increase in AST 59 2 7 0 Increase in creatinine 56 1 16 0 Increase in glucose 45 6 38 3 Decrease in sodium 35 5 21 4 Increase in calcium 29 3 19 2 Hematology Decrease in neutrophils 67 9 24 10 Decrease in hemoglobin 60 23 31 2 Decrease in lymphocytes 43 14 45 17 Decrease in platelets 34 6 4 0 TRITON2 The safety of RUBRACA 600 mg twice daily was evaluated in a single arm trial (TRITON2) [see Clinical Studies (14.2)]. TRITON2 enrolled 209 patients with HRR-mutated mCRPC, including 115 with BRCA-mutated mCRPC. Among the patients with BRCA -mutated mCRPC, the median duration of RUBRACA treatment was 6.5 months (range 0.5 to 26.7). Fatal adverse reactions occurred in 1.7% of patients who received RUBRACA, including acute respiratory distress syndrome and pneumonia (1 patient each). Permanent discontinuation of RUBRACA due to an adverse reaction occurred in 8% of patients. Dosage interruption of RUBRACA due to an adverse reaction occurred in 57% of patients. Dose reductions of RUBRACA occurred in 41% of patients. Tables 6 and 7 summarize the adverse reactions and laboratory abnormalities, respectively, in patients with BRCA -mutated mCRPC in TRITON2. Table 6. Adverse Reactions in ≥ 20% of Patients with BRCA-mutated mCRPC in TRITON2 a NCI CTCAE version 4.03. b Includes platelet count decreased c Includes blister, blood blister, dermatitis, dermatitis contact, eczema, genital rash, palmar-plantar erythrodysaesthesia syndrome, photosensitivity reaction, psoriasis, rash, rash maculo-papular, rash pruritic, skin exfoliation, skin lesion, urticaria Adverse Reaction Rubraca N = 115 Grades 1-4 a (%) Grades 3-4 (%) General disorders and administration site conditions Asthenia/Fatigue 62 9 Gastrointestinal disorders Nausea 52 3 Constipation 27 1 Vomiting 22 1 Diarrhea 20 0 Blood and lymphatic system disorders Anemia 43 25 Thrombocytopenia b 25 10 Metabolism and nutrition disorders Decreased appetite 28 2 Skin and subcutaneous tissue disorders Rash c 27 2 Other clinically relevant adverse reactions that occurred in less than 20% of patients included dyspnea, dizziness, bleeding, urinary tract infection, dysgeusia, dyspepsia, hypersensitivity (including flushing, asthma, choking sensation, periorbital swelling, swelling face, and wheezing), pneumonia, sepsis, ischemic cardiovascular events, renal failure, venous thromboembolism, and stomatitis. Table 7. Laboratory Abnormalities in ≥ 35% (Grades 1-4) and ≥ 2% (Grades 3-4) Worsening from Baseline in Patients with BRCA-mutated mCRPC in TRITON2 a Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available for 111 to 115 patients. b NCI CTCAE version 5.0; decrease in phosphate is graded using NCI CTACE Version 4.03 c Grade 3-4 ALT or AST elevation led to drug interruption in 4 patients, of which 1 had dose reduction upon rechallenge. Laboratory Parameter Rubraca N = 115 a Grades 1-4 b (%) Grades 3-4 (%) Clinical Chemistry Increase in ALT c 69 5 Decrease in phosphate 68 15 Increase in alkaline phosphatase 44 2 Increase in creatinine 43 2 Increase in triglycerides 42 5 Decrease in sodium 38 3 Hematologic Decrease in leukocytes 69 5 Decrease in absolute neutrophil count 62 5"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Effect of Rubraca on Other Drugs Certain CYP1A2, CYP3A, CYP2C9, or CYP2C19 Substrates Concomitant administration of Rubraca with CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates can increase the systemic exposure of these substrates [see Clinical Pharmacology ( 12.3 )] , which may increase the frequency or severity of adverse reactions of these substrates. If concomitant administration is unavoidable between Rubraca and substrates of these enzymes where minimal concentration changes may lead to serious adverse reactions, decrease the substrate dosage in accordance with the approved prescribing information. If concomitant administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.","7.1 Effect of Rubraca on Other Drugs Certain CYP1A2, CYP3A, CYP2C9, or CYP2C19 Substrates Concomitant administration of Rubraca with CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates can increase the systemic exposure of these substrates [see Clinical Pharmacology ( 12.3 )] , which may increase the frequency or severity of adverse reactions of these substrates. If concomitant administration is unavoidable between Rubraca and substrates of these enzymes where minimal concentration changes may lead to serious adverse reactions, decrease the substrate dosage in accordance with the approved prescribing information. If concomitant administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.","Certain CYP1A2, CYP3A, CYP2C9, or CYP2C19 Substrates Concomitant administration of Rubraca with CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates can increase the systemic exposure of these substrates [see Clinical Pharmacology ( 12.3 )] , which may increase the frequency or severity of adverse reactions of these substrates. If concomitant administration is unavoidable between Rubraca and substrates of these enzymes where minimal concentration changes may lead to serious adverse reactions, decrease the substrate dosage in accordance with the approved prescribing information. If concomitant administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring."],"mechanism_of_action":["12.1 Mechanism of Action Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cancer cell death. Increased rucaparib-induced cytotoxicity and anti-tumor activity was observed in tumor cell lines with deficiencies in BRCA1/2 and other DNA repair genes. Rucaparib has been shown to decrease tumor growth in mouse xenograft models of human cancer with or without deficiencies in BRCA ."],"recent_major_changes":["Indications and Usage ( 1.2 ) 12/2025 Warnings and Precautions ( 5.1 ) 12/2025"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cancer cell death. Increased rucaparib-induced cytotoxicity and anti-tumor activity was observed in tumor cell lines with deficiencies in BRCA1/2 and other DNA repair genes. Rucaparib has been shown to decrease tumor growth in mouse xenograft models of human cancer with or without deficiencies in BRCA . 12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of rucaparib has not fully been characterized. Cardiac Electrophysiology A positive concentration-QTc relationship was observed in patients who were administered continuous dosages of Rubraca ranging from 40 mg once daily (0.03 times the approved recommended dosage) to 840 mg twice daily (1.4 times the approved recommended dosage). The mean (90% confidence interval [CI]) QTcF increase from baseline at steady state of Rubraca 600 mg twice daily was 14.9 msec (11.1, 18.7 msec). 12.3 Pharmacokinetics The AUC and C max of rucaparib demonstrated linear pharmacokinetics over a dose range from 240 mg to 840 mg twice daily (0.4 times to 1.4 times the approved recommended dosage). The mean (coefficient of variation [CV]) steady-state rucaparib C max is 1,940 ng/mL (54%) and AUC 0-12h is 16,900 h×ng/mL (54%) at the approved recommended dosage. The mean AUC accumulation ratio is 3.5 to 6.2 fold. Absorption The median T max (min, max) at the steady state is 1.9 hours (0, 5.98) at the approved recommended dosage. The mean (min, max) absolute bioavailability is 36% (30%, 45%). Effect of Food Following a high-fat meal (approximately 800-1000 calories, including approximately 250 calories from carbohydrates, approximately 500-600 calories from fat, approximately 150 calories from protein), the C max was increased by 20%, AUC 0-24h was increased by 38%, and the T max was delayed by 2.5 hours, as compared to fasted conditions [see Dosage and Administration ( 2.2 )] . Distribution The mean apparent volume of distribution is 2300 L (21%). Rucaparib is 70% bound to human plasma proteins in vitro. Rucaparib preferentially distributed to red blood cells with a blood-to-plasma concentration ratio of 1.8. Elimination The mean apparent total clearance at steady state is 44.2 L/h (45%) and the mean terminal elimination half-life is 26 (39%) hours. Metabolism In vitro, rucaparib is primarily metabolized by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. In addition to CYP-based oxidation, rucaparib also undergoes N-demethylation, N-methylation, and glucuronidation. Excretion Following a single oral dose of radiolabeled rucaparib, unchanged rucaparib accounted for 64% of the radioactivity. Rucaparib accounted for 45% and 95% of radioactivity in urine and feces, respectively. Specific Populations Age (20 to 86 years), race (White, Black, and Asian), sex, body weight (41 to 171 kg), mild to moderate renal impairment (CLcr ≥ 30 mL/min), mild hepatic impairment (total bilirubin < ULN and AST > ULN or total bilirubin 1 to 1.5 x ULN and any AST), and CYP2D6 or CYP1A2 genotype polymorphisms did not have a clinically meaningful effect on the pharmacokinetics of rucaparib. The effect of severe renal impairment (CLcr 15 to 29 mL/min), end-stage renal disease (CLcr < 15 mL/min), or severe hepatic impairment (total bilirubin > 3 x ULN and any AST) has not been studied. Hepatic Impairment Moderate hepatic impairment (total bilirubin > 1.5 to 3 x ULN and any AST) increased rucaparib AUC by 45%, but had no effect on C max compared to patients with normal hepatic function. Drug Interaction Studies Clinical Studies and Model-Informed Approaches Effect of Other Drugs on Rucaparib Concomitant administration of Rubraca with a proton pump inhibitor had no clinically meaningful effect on steady-state concentrations of rucaparib. Effect of Rucaparib on Other Drugs Concomitant administration of Rubraca with rosuvastatin (BCRP substrate) had no clinically meaningful effect on the concentrations of rosuvastatin. Coadministration of Rubraca with the following substrates increased the C max of each coadministered substrate by ≤ 1.1-fold and increased the AUC of each substrate as follows: Caffeine (CYP1A2): by 2.6-fold Midazolam (CYP3A4): by 1.4-fold Warfarin (CYP2C9): by 1.5-fold Omeprazole (CYP2C19): by 1.6-fold Digoxin (P-glycoprotein): by 1.2-fold Concomitant administration of Rubraca with an oral contraceptive containing ethinylestradiol and levonorgestrel (CYP3A substrates): increased ethinylestradiol AUC by 1.4-fold and levonorgestrel AUC by 1.6-fold, but did not have a clinically meaningful effect on their C max . In Vitro Studies Cytochrome P450 (CYP) Enzymes : Rucaparib inhibited CYP2C8 and CYP2D6 and induced CYP1A2. UDP-glucuronosyltransferase (UGT) Enzymes : Rucaparib inhibited UGT1A1. Transporter Systems : Rucaparib is a substrate of P-gp and BCRP. Rucaparib is not a substrate of OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. Rucaparib inhibited OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, OCT1, OCT2, and MRP4. Rucaparib did not inhibit MRP2, MRP3, or BSEP."],"indications_and_usage":["1 INDICATIONS AND USAGE RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].","1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )]."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): MDS/AML occurred in patients exposed to RUBRACA, and some cases were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Interrupt or reduce the dose based on severity of reaction. Discontinue if MDS/AML is confirmed. ( 2.3 , 5.1 ) Embryo-Fetal Toxicity: RUBRACA can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. ( 5.2 , 8.1 , 8.3 ) 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) occur in patients treated with RUBRACA, and are potentially fatal adverse reactions. In 2141 treated patients with ovarian and prostate cancer [see Adverse Reactions ( 6.1 )], MDS/AML occurred in 34 patients (1.6%), including those in long term follow-up. Of these, 14 occurred during treatment or during the 28-day safety follow-up (0.7%). The duration of RUBRACA treatment prior to the diagnosis of MDS/AML ranged from < 2 months to approximately 72 months. The cases were typical of secondary MDS/cancer therapy-related AML; in all cases, patients had received previous platinum-containing chemotherapy regimens and/or other DNA damaging agents. In ARIEL3, of patients with a germline and/or somatic BRCA mutation treated with RUBRACA, MDS/AML occurred in 9 out of 129 (7%) patients treated with RUBRACA and 4 out of 66 (6%) patients treated with placebo. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.2 to 4.7 years. In TRITON3, MDS/AML occurred in 2 out of 201 patients (1%) with a BRCA mutation treated with RUBRACA. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.4 to 2.3 years. Do not start Rubraca until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood counts for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities (> 4 weeks), interrupt Rubraca or reduce dose according to Table 1 [see Dosage and Administration ( 2.3 )] and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks or if MDS/AML is suspected, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Rubraca. 5.2 Embryo-Fetal Toxicity Rubraca can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings from animal studies. In an animal reproduction study, administration of rucaparib to pregnant rats during the period of organogenesis resulted in embryo-fetal death at exposures that were 0.04 times the AUC 0-24h in patients receiving the recommended human dose of 600 mg twice daily. Apprise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Rubraca [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )]. Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of Rubraca [see Use in Specific Populations ( 8.1 , 8.3 )].","5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) occur in patients treated with RUBRACA, and are potentially fatal adverse reactions. In 2141 treated patients with ovarian and prostate cancer [see Adverse Reactions ( 6.1 )], MDS/AML occurred in 34 patients (1.6%), including those in long term follow-up. Of these, 14 occurred during treatment or during the 28-day safety follow-up (0.7%). The duration of RUBRACA treatment prior to the diagnosis of MDS/AML ranged from < 2 months to approximately 72 months. The cases were typical of secondary MDS/cancer therapy-related AML; in all cases, patients had received previous platinum-containing chemotherapy regimens and/or other DNA damaging agents. In ARIEL3, of patients with a germline and/or somatic BRCA mutation treated with RUBRACA, MDS/AML occurred in 9 out of 129 (7%) patients treated with RUBRACA and 4 out of 66 (6%) patients treated with placebo. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.2 to 4.7 years. In TRITON3, MDS/AML occurred in 2 out of 201 patients (1%) with a BRCA mutation treated with RUBRACA. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.4 to 2.3 years. Do not start Rubraca until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood counts for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities (> 4 weeks), interrupt Rubraca or reduce dose according to Table 1 [see Dosage and Administration ( 2.3 )] and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks or if MDS/AML is suspected, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Rubraca.","5.2 Embryo-Fetal Toxicity Rubraca can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings from animal studies. In an animal reproduction study, administration of rucaparib to pregnant rats during the period of organogenesis resulted in embryo-fetal death at exposures that were 0.04 times the AUC 0-24h in patients receiving the recommended human dose of 600 mg twice daily. Apprise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Rubraca [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )]. Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of Rubraca [see Use in Specific Populations ( 8.1 , 8.3 )]."],"clinical_studies_table":["
Table 8. Efficacy Results in Patients with tBRCA-mutated Ovarian Cancer – ARIEL3 (Investigator Assessment) a
at BRCA includes all patients with a deleterious germline or somatic BRCA mutation, as determined by the CTA.
Rubraca N=130Placebo N=66
Progression Free Survival
Number of events, n (%)67 (52%)56 (85%)
Median in months (95% CI)16.6 (13.4-22.9)5.4 (3.4-6.7)
HR (95% CI)0.23 (0.16, 0.34)
p-value< 0.0001
","
Table 9. Efficacy Results from the BRCAm Subgroup of the TRITON3 Study
EndpointRubracaN=201 fARPI or DocetaxelN=101 f
Radiographic Progression Free Survival a
Number of events, n (%)115 (57%)67 (66%)
Median in months (95% CI)11.2 (9.2-13.8)6.4 (5.4-8.3)
Hazard ratiob (95% CI)0.50 (0.36, 0.69)
p-value c< 0.0001
Overall Survival d
Number of events, n (%)152 (76%)74 (73%)
Median in months (95% CI)23.2 (19.1, 25.2)21.2 (18.0, 23.1)
Hazard ratio b(95% CI) 0.91 (0.68, 1.20)
p-value cNS
Confirmed Overall Response Rate a,e
N=82N=41
Overall response rate (95% CI)45.1 (34.1, 56.5)17.1 (7.2, 32.1)
Number of complete responses, n (%)10 (12.2)2 (4.9)
Number of partial responses, n (%)27 (32.9)5 (12.2)
NS=Not significant
aBased on IRR assessment.
bCox proportional hazards model stratified by ECOG Status (0 or 1) and type of mutation ( BRCA1 or BRCA2).
cP-value based on the stratified log-rank test
dBased on pre-specified final analysis.
eBased on patients with measurable disease at baseline per IRR assessment. Responses are based on soft tissue and bone lesion assessment.
fBased on the BRCA mutation status used at the randomization. This excludes one patient with a reported ATM mutation at randomization but found to have a BRCA2 mutation based on the verified source.
","
Table 10. Efficacy Results in Patients with BRCA-mutated mCRPC - TRITON2 (IRR-assessed)
NE = not evaluable
aDefined per modified RECIST v1.1 criteria and with no confirmed bone progression per PCWG3.
bThe range for the DOR was 1.7-24+ months. Fifteen of the 27 (56%) patients with a confirmed objective response had a DOR of ≥6 months.
Rubraca (N = 62)
Confirmed Objective Response Rate (95% CI) a44% (31, 57)
Median DOR in months (95% CI) bNE (6.4, NE)
","
Table 8. Efficacy Results in Patients with tBRCA-mutated Ovarian Cancer – ARIEL3 (Investigator Assessment) a
at BRCA includes all patients with a deleterious germline or somatic BRCA mutation, as determined by the CTA.
Rubraca N=130Placebo N=66
Progression Free Survival
Number of events, n (%)67 (52%)56 (85%)
Median in months (95% CI)16.6 (13.4-22.9)5.4 (3.4-6.7)
HR (95% CI)0.23 (0.16, 0.34)
p-value< 0.0001
","
Table 9. Efficacy Results from the BRCAm Subgroup of the TRITON3 Study
EndpointRubracaN=201 fARPI or DocetaxelN=101 f
Radiographic Progression Free Survival a
Number of events, n (%)115 (57%)67 (66%)
Median in months (95% CI)11.2 (9.2-13.8)6.4 (5.4-8.3)
Hazard ratiob (95% CI)0.50 (0.36, 0.69)
p-value c< 0.0001
Overall Survival d
Number of events, n (%)152 (76%)74 (73%)
Median in months (95% CI)23.2 (19.1, 25.2)21.2 (18.0, 23.1)
Hazard ratio b(95% CI) 0.91 (0.68, 1.20)
p-value cNS
Confirmed Overall Response Rate a,e
N=82N=41
Overall response rate (95% CI)45.1 (34.1, 56.5)17.1 (7.2, 32.1)
Number of complete responses, n (%)10 (12.2)2 (4.9)
Number of partial responses, n (%)27 (32.9)5 (12.2)
NS=Not significant
aBased on IRR assessment.
bCox proportional hazards model stratified by ECOG Status (0 or 1) and type of mutation ( BRCA1 or BRCA2).
cP-value based on the stratified log-rank test
dBased on pre-specified final analysis.
eBased on patients with measurable disease at baseline per IRR assessment. Responses are based on soft tissue and bone lesion assessment.
fBased on the BRCA mutation status used at the randomization. This excludes one patient with a reported ATM mutation at randomization but found to have a BRCA2 mutation based on the verified source.
","
Table 10. Efficacy Results in Patients with BRCA-mutated mCRPC - TRITON2 (IRR-assessed)
NE = not evaluable
aDefined per modified RECIST v1.1 criteria and with no confirmed bone progression per PCWG3.
bThe range for the DOR was 1.7-24+ months. Fifteen of the 27 (56%) patients with a confirmed objective response had a DOR of ≥6 months.
Rubraca (N = 62)
Confirmed Objective Response Rate (95% CI) a44% (31, 57)
Median DOR in months (95% CI) bNE (6.4, NE)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with rucaparib. Rucaparib was clastogenic in an in vitro chromosomal aberration assay in cultured human lymphocytes. The clastogenic response in mitotically-stimulated cells was anticipated based on the mechanism of action of rucaparib and indicates potential genotoxicity in humans. Rucaparib was not mutagenic in a bacterial reverse mutation (Ames) test. Fertility studies with rucaparib have not been conducted. In 3-month repeat-dose general toxicology studies, rucaparib had no effects on male and female reproductive organs at doses up to 100 mg/kg/day and 20 mg/kg/day in rats and dogs, respectively. These dose levels resulted in systemic exposures of approximately 0.3 and 0.09 times the human exposure (AUC 0-24h ), respectively, at the recommended dose."],"adverse_reactions_table":["
Table 2. Adverse Reactions in ≥ 20% of Patients with BRCA-mutated Ovarian Cancer in ARIEL3
aNational Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03)
bConsists of grouped related terms that reflect the medical concept of the adverse reaction
Adverse reactionsRUBRACA N=129Placebo N=66
Grades 1-4a %Grades 3-4 %Grades 1-4a %Grades 3-4 %
Gastrointestinal Disorders
Nausea792290
Abdominal pain/distention b483492
Constipation394362
Vomiting374140
Diarrhea342180
Stomatitis b280.8120
General Disorders and Administration Site Conditions
Fatigue/asthenia749525
Skin and Subcutaneous Tissue Disorders
Rash b450230
Nervous System Disorders
Dysgeusia33060
Headache220152
Investigations
ALT/AST elevation331630
Blood and Lymphatic System Disorders
Anemia412660
Thrombocytopenia35630
Neutropenia22860
Respiratory, Thoracic, and Mediastinal Disorders
Nasopharyngitis/Upper respiratory tract infection b290202
Metabolism and Nutrition Disorders
Decreased appetite232140
","
aPatients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.
bNCI CTCAE version 4.03.
Laboratory ParameteraRUBRACA N=129Placebo N=66
Grades 1-4b %Grades 3-4 %Grades 1-4b %Grades 3-4 %
Chemistry
Increase in creatinine960890
Increase in ALT671160
Increase in AST59160
Increase in cholesterol393200
Increase in Alkaline Phosphatase39030
Hematology
Decrease in hemoglobin6118142
Decrease in platelets47280
Decrease in leukocytes393230
Decrease in neutrophils386182
Decrease in lymphocytes337142
","
Table 4. Adverse Reactions in ≥ 10% of Patients with BRCA-mutated mCRPC in TRITON3
a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0)
b Includes multiple related terms
Adverse ReactionRUBRACA N=201 ARPI or Docetaxel N=97
Grades 1-4 a (%) Grades 3-4 (%) Grades 1-4 a (%) Grades 3-4 (%)
General disorders and administration site conditions
Fatigue/Asthenia6176510
Edema b180200
Musculoskeletal and connective tissue disorders
Musculoskeletal pain b537578
Gastrointestinal disorders
Nausea512221
Diarrhea312291
Constipation312171
Vomiting251101
Abdominal pain b171101
Metabolism and nutrition disorders
Decreased appetite341202
Respiratory, thoracic and mediastinal disorders
Dyspnea b191131
Nervous system disorders
Dysgeusia b180120
Dizziness b16190
Headache b12090
Peripheral neuropathy b121261
Investigations
Weight decreased161130
Skin and subcutaneous tissue disorders
Rash b13160
Photosensitivity reaction b12100
Infections and infestations
Urinary tract infection b10341
","
Table 5. Laboratory Abnormalities in ≥ 25% of Patients with BRCA-mutated mCRPC in TRITON3
aDenominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available for 192 to 201 patients in the RUBRACA Arm and 94 to 97 patients in the ARPI or Docetaxel Arm.
bNCI CTCAE version 5.0; decrease in phosphate is graded using NCI CTACE Version 4.03
Laboratory ParameterRubraca N=201 aARPI or Docetaxel N=97 a
Grades 1-4 b (%) Grades 3-4 (%) Grades 1-4 b (%) Grades 3-4 (%)
Chemistry
Increase in ALT68480
Decrease in phosphate648455
Increase in AST59270
Increase in creatinine561160
Increase in glucose456383
Decrease in sodium355214
Increase in calcium293192
Hematology
Decrease in neutrophils6792410
Decrease in hemoglobin6023312
Decrease in lymphocytes43144517
Decrease in platelets34640
","
Table 6. Adverse Reactions in ≥ 20% of Patients with BRCA-mutated mCRPC in TRITON2
aNCI CTCAE version 4.03.
bIncludes platelet count decreased
cIncludes blister, blood blister, dermatitis, dermatitis contact, eczema, genital rash, palmar-plantar erythrodysaesthesia syndrome, photosensitivity reaction, psoriasis, rash, rash maculo-papular, rash pruritic, skin exfoliation, skin lesion, urticaria
Adverse ReactionRubraca N = 115
Grades 1-4 a (%) Grades 3-4 (%)
General disorders and administration site conditions
Asthenia/Fatigue629
Gastrointestinal disorders
Nausea523
Constipation271
Vomiting221
Diarrhea200
Blood and lymphatic system disorders
Anemia4325
Thrombocytopenia b2510
Metabolism and nutrition disorders
Decreased appetite282
Skin and subcutaneous tissue disorders
Rash c272
","
Table 7. Laboratory Abnormalities in ≥ 35% (Grades 1-4) and ≥ 2% (Grades 3-4) Worsening from Baseline in Patients with BRCA-mutated mCRPC in TRITON2
aDenominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available for 111 to 115 patients.
bNCI CTCAE version 5.0; decrease in phosphate is graded using NCI CTACE Version 4.03
cGrade 3-4 ALT or AST elevation led to drug interruption in 4 patients, of which 1 had dose reduction upon rechallenge.
Laboratory ParameterRubraca N = 115 a
Grades 1-4 b (%) Grades 3-4 (%)
Clinical Chemistry
Increase in ALT c695
Decrease in phosphate6815
Increase in alkaline phosphatase442
Increase in creatinine432
Increase in triglycerides425
Decrease in sodium383
Hematologic
Decrease in leukocytes695
Decrease in absolute neutrophil count625
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Patient Information ). MDS/AML : Advise patients to contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions. These may be signs of hematological toxicity or a more serious uncommon bone marrow problem called ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukemia’ (AML) which have been reported in patients treated with RUBRACA [see Warnings and Precautions (5.1)]. Embryo-Fetal Toxicity : Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after receiving the last dose of RUBRACA. Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months after receiving the last dose of RUBRACA. Advise male patients not to donate sperm during therapy and for 3 months following the last dose of RUBRACA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.1, 8.3)]. Photosensitivity : Advise patients to use appropriate sun protection due to the increased susceptibility to sunburn while taking RUBRACA [see Adverse Drug Reactions (6.1)]. Lactation : Advise females not to breastfeed during treatment and for 2 weeks after the last dose of RUBRACA [see Use in Specific Populations (8.2)]. Dosing Instructions : Instruct patients to take RUBRACA orally twice daily with or without food. Doses should be taken approximately 12 hours apart. Advise patients that if a dose of RUBRACA is missed or if the patient vomits after taking a dose of RUBRACA, patients should not take an extra dose, but take the next dose at the regular time [see Dosage and Administration (2.2)]. Manufactured for: pharmaand GmbH Taborstrasse 1 1020 Wien Austria Distributed by: Summit SD, LLC 255 Northwest Victoria Drive, Suite A Lee’s Summit, MO 64086 RUBRACA is a registered trademark of pharma&."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended dose is 600 mg orally twice daily with or without food. ( 2.2 ) Continue treatment until disease progression or unacceptable toxicity. ( 2.2 ) For adverse reactions, consider interruption of treatment or dose reduction. ( 2.3 ) Patients receiving RUBRACA for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ( 2.2 ) 2.1 Patient Selection Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer Select patients for the maintenance treatment of recurrent ovarian cancer with RUBRACA based on the presence of a deleterious BRCA mutation (germline and/or somatic) [see Clinical Studies ( 14.1 )]. An FDA-approved test for the detection of deleterious germline and/or somatic BRCA mutations is not currently available. Treatment of BRCA -mutated mCRPC after Androgen Receptor-directed Therapy Select patients for the treatment of mCRPC with RUBRACA based on the presence of a deleterious BRCA mutation (germline and/or somatic) in plasma specimens [see Clinical Studies ( 14.2 )]. A negative result from a plasma specimen does not mean that the patient’s tumor is negative for BRCA mutations. Should the plasma specimen have a negative result, consider performing further genomic testing using tumor specimens as clinically indicated. Information on the FDA-approved tests for the detection of a BRCA mutation in patients with ovarian cancer or with prostate cancer is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dose The recommended dose of Rubraca is 600 mg (two 300 mg tablets) taken orally twice daily with or without food, for a total daily dose of 1,200 mg. ( 2.2 ) Continue treatment until disease progression or unacceptable toxicity. ( 2.2 ) For adverse reactions, consider interruption of treatment or dose reduction. ( 2.3 ) Patients receiving RUBRACA for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ( 2.2 ) 2.3 Dose Modifications for Adverse Reactions To manage adverse reactions, consider interruption of treatment or dose reduction. Recommended Rubraca dose modifications for adverse reactions are indicated in Table 1 . Table 1. Recommended Dose Modifications for Adverse Reactions Dose Reduction Dose Starting Dose 600 mg twice daily (two 300 mg tablets) First Dose Reduction 500 mg twice daily (two 250 mg tablets) Second Dose Reduction 400 mg twice daily (two 200 mg tablets) Third Dose Reduction 300 mg twice daily (one 300 mg tablet)","2.1 Patient Selection Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer Select patients for the maintenance treatment of recurrent ovarian cancer with RUBRACA based on the presence of a deleterious BRCA mutation (germline and/or somatic) [see Clinical Studies ( 14.1 )]. An FDA-approved test for the detection of deleterious germline and/or somatic BRCA mutations is not currently available. Treatment of BRCA -mutated mCRPC after Androgen Receptor-directed Therapy Select patients for the treatment of mCRPC with RUBRACA based on the presence of a deleterious BRCA mutation (germline and/or somatic) in plasma specimens [see Clinical Studies ( 14.2 )]. A negative result from a plasma specimen does not mean that the patient’s tumor is negative for BRCA mutations. Should the plasma specimen have a negative result, consider performing further genomic testing using tumor specimens as clinically indicated. Information on the FDA-approved tests for the detection of a BRCA mutation in patients with ovarian cancer or with prostate cancer is available at: http://www.fda.gov/CompanionDiagnostics.","2.2 Recommended Dose The recommended dose of Rubraca is 600 mg (two 300 mg tablets) taken orally twice daily with or without food, for a total daily dose of 1,200 mg. ( 2.2 ) Continue treatment until disease progression or unacceptable toxicity. ( 2.2 ) For adverse reactions, consider interruption of treatment or dose reduction. ( 2.3 ) Patients receiving RUBRACA for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ( 2.2 )","2.3 Dose Modifications for Adverse Reactions To manage adverse reactions, consider interruption of treatment or dose reduction. Recommended Rubraca dose modifications for adverse reactions are indicated in Table 1 . Table 1. Recommended Dose Modifications for Adverse Reactions Dose Reduction Dose Starting Dose 600 mg twice daily (two 300 mg tablets) First Dose Reduction 500 mg twice daily (two 250 mg tablets) Second Dose Reduction 400 mg twice daily (two 200 mg tablets) Third Dose Reduction 300 mg twice daily (one 300 mg tablet)"],"spl_product_data_elements":["Rubraca rucaparib SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED TALC FD&C BLUE NO. 1 FD&C BLUE NO. 2 CELLULOSE, MICROCRYSTALLINE RUCAPARIB CAMSYLATE RUCAPARIB ROUND C2 BLUE Rubraca rucaparib CELLULOSE, MICROCRYSTALLINE SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED TALC FERRIC OXIDE YELLOW RUCAPARIB CAMSYLATE RUCAPARIB YELLOW OVAL C3 Rubraca rucaparib CELLULOSE, MICROCRYSTALLINE SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED TALC RUCAPARIB CAMSYLATE RUCAPARIB WHITE DIAMOND C25"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets (200 mg): blue, round, immediate-release, film-coated, debossed with “C2”. Tablets (250 mg): white, diamond, immediate-release, film-coated, debossed with “C25”. Tablets (300 mg): yellow, oval, immediate-release, film-coated, debossed with “C3”. Tablets: 200 mg, 250 mg, and 300 mg ( 3 )"],"recent_major_changes_table":["
Indications and Usage ( 1.2) 12/2025
Warnings and Precautions ( 5.1) 12/2025
"],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: December 2025 PATIENT INFORMATION Rubraca ® (roo-brah'-kah) (rucaparib) tablets What is the most important information I should know about Rubraca? Rubraca may cause serious side effects including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca. Symptoms of low blood cell counts are common during treatment with Rubraca, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca: weakness weight loss fever frequent infections blood in urine or stool shortness of breath feeling very tired bruising or bleeding more easily Your healthcare provider will do blood tests to check your blood cell counts: before treatment with Rubraca. every month during treatment with Rubraca. weekly if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve. See \"What are possible side effects of Rubraca?\" for more information about side effects. What is Rubraca? Rubraca is a prescription medicine used in adults for: the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene when your cancer has come back and you are in response (complete or partial response) to a platinum-based chemotherapy. the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone): that has spread to other parts of the body, and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you. It is not known if Rubraca is safe and effective in children. Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca. If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca. Females who are able to become pregnant: Your healthcare provider may do a pregnancy test before you start treatment with Rubraca Use effective birth control (contraception) during treatment with Rubraca and for 6 months after the last dose of Rubraca. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with Rubraca. Males with female partners who are pregnant or able to become pregnant: Use effective birth control (contraception) during treatment with Rubraca and for 3 months after the last dose of Rubraca. Do not donate sperm during treatment with Rubraca and for 3 months after the last dose of Rubraca. are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Rubraca may affect the way other medicines work. How should I take Rubraca? Take Rubraca exactly as your healthcare provider tells you. Your healthcare provider may temporarily stop treatment with Rubraca or change your dose of Rubraca if you have side effects. Do not change your dose or stop taking Rubraca unless your healthcare provider tells you to. Take Rubraca 2 times a day. Each dose should be taken about 12 hours apart. Take Rubraca with or without food. If you are taking Rubraca for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with Rubraca unless you have had a surgery to lower the amount of testosterone in your body (surgical castration). If you miss a dose of Rubraca, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose. If you vomit after taking a dose of Rubraca, do not take an extra dose. Take your next dose at your usual time. If you take too much Rubraca, call your healthcare provider or go to the nearest emergency room right away. What should I avoid while taking Rubraca? Avoid spending time in sunlight. Rubraca can make your skin sensitive to the sun (photosensitivity). You may sunburn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight. What are the possible side effects of Rubraca? Rubraca may cause serious side effects. See \"What is the most important information I should know about Rubraca?\" The most common side effects of Rubraca in people with ovarian cancer include: nausea tiredness or weakness decrease in hemoglobin (anemia) changes in liver and kidney function tests vomiting diarrhea decreased appetite low blood cell counts changes in how food tastes shortness of breath dizziness indigestion reaction to sunlight The most common side effects of Rubraca in people with prostate cancer include: tiredness or weakness muscle and joint pain nausea decrease in hemoglobin (anemia) decreased appetite changes in liver and kidney function tests constipation diarrhea vomiting low blood cell counts shortness of breath swelling in your legs and feet dizziness decreased weight stomach area (abdominal) pain changes in how food tastes rash tingling sensation and numbness urinary tract infection cough headache bleeding reaction to sunlight These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Rubraca? Store Rubraca at room temperature between 68°F to 77°F (20°C to 25°C). Keep Rubraca and all medicines out of the reach of children. General information about the safe and effective use of Rubraca. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Rubraca for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about Rubraca. What are the ingredients in Rubraca? Active ingredient: rucaparib Inactive ingredients: microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The film coating contains polyvinyl alcohol, titanium dioxide, polyethylene glycol/macrogol, and talc. The blue film coating contains brilliant blue aluminum lake and indigo carmine aluminum lake. The yellow film coating contains yellow iron oxide. Manufactured for: pharmaand GmbH, Taborstrasse 1, 1020 Wien, Austria Distributed by: Summit SD LLC, 420 NW Capital Drive, Lee’s Summit, MO 64086 For more information call tel: 1-800-506-8501"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, Rubraca can cause fetal harm when administered to pregnant women. There are no available data in pregnant women to inform the drug-associated risk. In an animal reproduction study, administration of rucaparib to pregnant rats during organogenesis resulted in embryo-fetal death at maternal exposures that were 0.04 times the AUC 0-24h in patients receiving the recommended dose of 600 mg twice daily [see Data] . Apprise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a dose range-finding embryo-fetal development study, pregnant rats received oral doses of 50, 150, 500, or 1000 mg/kg/day of rucaparib during the period of organogenesis. Post-implantation loss (100% early resorptions) was observed in all animals at doses greater than or equal to 50 mg/kg/day (with maternal systemic exposures approximately 0.04 times the human exposure at the recommended dose based on AUC 0-24h ). 8.2 Lactation Risk Summary There is no information regarding the presence of rucaparib in human milk, or on its effects on milk production or the breast-fed child. Because of the potential for serious adverse reactions in breast-fed children from Rubraca, advise lactating women not to breastfeed during treatment with Rubraca and for 2 weeks following the last dose. 8.3 Females and Males of Reproductive Potential Rubraca can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Pregnancy Testing Pregnancy testing is recommended for females of reproductive potential prior to initiating Rubraca. Contraception Females Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Rubraca [see Use in Specific Populations ( 8.1 )] . Males Based on findings in genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective methods of contraception during treatment and for 3 months following last dose of Rubraca. Advise male patients not to donate sperm during therapy and for 3 months following the last dose of Rubraca [see Use in Specific Populations ( 8.1 ) and Nonclinical Toxicology ( 13.1 )]. 8.4 Pediatric Use The safety and effectiveness of Rubraca in pediatric patients have not been established. 8.5 Geriatric Use Of the 937 patients with ovarian cancer who received Rubraca in clinical trials including ARIEL3, 41% were age 65 or older and 10% were 75 years or older. No major differences in safety were observed between younger and older patients with ovarian cancer. Of the 209 patients with mCRPC who received Rubraca in TRITON2, 77% were age 65 or older and 33% were 75 years or older. No major differences in safety were observed between younger and older patients with mCRPC. 8.6 Renal Impairment No dosage modification is recommended for patients with mild to moderate renal impairment (creatinine clearance [CLcr] between 30 and 89 mL/min, as estimated by the Cockcroft-Gault method) [see Clinical Pharmacology ( 12.3 )]. Rubraca has not been studied in patients with CLcr < 30 mL/min or patients on dialysis. 8.7 Hepatic Impairment No dosage modification is recommended for patients with mild to moderate hepatic impairment (total bilirubin ≤ 3 x upper limit of normal [ULN] or AST > ULN) [see Clinical Pharmacology ( 12.3 )] . Rubraca has not been studied in patients with severe hepatic impairment (total bilirubin > 3 x ULN and any AST)."],"dosage_and_administration_table":["
Table 1. Recommended Dose Modifications for Adverse Reactions
Dose ReductionDose
Starting Dose600 mg twice daily (two 300 mg tablets)
First Dose Reduction500 mg twice daily (two 250 mg tablets)
Second Dose Reduction400 mg twice daily (two 200 mg tablets)
Third Dose Reduction300 mg twice daily (one 300 mg tablet)
","
Table 1. Recommended Dose Modifications for Adverse Reactions
Dose ReductionDose
Starting Dose600 mg twice daily (two 300 mg tablets)
First Dose Reduction500 mg twice daily (two 250 mg tablets)
Second Dose Reduction400 mg twice daily (two 200 mg tablets)
Third Dose Reduction300 mg twice daily (one 300 mg tablet)
"],"spl_patient_package_insert_table":["
This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: December 2025
PATIENT INFORMATION Rubraca®(roo-brah'-kah) (rucaparib) tablets
What is the most important information I should know about Rubraca?Rubraca may cause serious side effects including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML).Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca. Symptoms of low blood cell counts are common during treatment with Rubraca, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca:
weaknessweight lossfeverfrequent infectionsblood in urine or stoolshortness of breathfeeling very tiredbruising or bleeding more easily
Your healthcare provider will do blood tests to check your blood cell counts: before treatment with Rubraca.every month during treatment with Rubraca.weekly if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.See "What are possible side effects of Rubraca?"for more information about side effects.
What is Rubraca? Rubraca is a prescription medicine used in adults for: the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCAgene when your cancer has come back and you are in response (complete or partial response) to a platinum-based chemotherapy. the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone): that has spread to other parts of the body, andhas a certain type of inherited (germline) or acquired (somatic) abnormal BRCAgene, and you have been treated with certain medicines for your cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you. It is not known if Rubraca is safe and effective in children.
Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you:are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca. If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca. Females who are able to become pregnant: Your healthcare provider may do a pregnancy test before you start treatment with RubracaUse effective birth control (contraception) during treatment with Rubraca and for 6 months after the last dose of Rubraca. Talk to your healthcare provider about birth control methods that may be right for you.Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with Rubraca. Males with female partners who are pregnant or able to become pregnant: Use effective birth control (contraception) during treatment with Rubraca and for 3 months after the last dose of Rubraca.Do not donate sperm during treatment with Rubraca and for 3 months after the last dose of Rubraca.are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Rubraca may affect the way other medicines work.
How should I take Rubraca?Take Rubraca exactly as your healthcare provider tells you.Your healthcare provider may temporarily stop treatment with Rubraca or change your dose of Rubraca if you have side effects. Do not change your dose or stop taking Rubraca unless your healthcare provider tells you to.Take Rubraca 2 times a day. Each dose should be taken about 12 hours apart.Take Rubraca with or without food.If you are taking Rubraca for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with Rubraca unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).If you miss a dose of Rubraca, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose.If you vomit after taking a dose of Rubraca, do not take an extra dose. Take your next dose at your usual time.If you take too much Rubraca, call your healthcare provider or go to the nearest emergency room right away.
What should I avoid while taking Rubraca? Avoid spending time in sunlight. Rubraca can make your skin sensitive to the sun (photosensitivity). You may sunburn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.
What are the possible side effects of Rubraca?Rubraca may cause serious side effects.See "What is the most important information I should know about Rubraca?" The most common side effects of Rubraca in people with ovarian cancer include:
nauseatiredness or weaknessdecrease in hemoglobin (anemia)changes in liver and kidney function testsvomitingdiarrheadecreased appetitelow blood cell countschanges in how food tastesshortness of breathdizzinessindigestionreaction to sunlight
The most common side effects of Rubraca in people with prostate cancer include:
tiredness or weaknessmuscle and joint painnauseadecrease in hemoglobin (anemia)decreased appetitechanges in liver and kidney function testsconstipationdiarrheavomitinglow blood cell countsshortness of breathswelling in your legs and feetdizzinessdecreased weightstomach area (abdominal) painchanges in how food tastesrashtingling sensation and numbnessurinary tract infectioncoughheadachebleedingreaction to sunlight
These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Rubraca?Store Rubraca at room temperature between 68°F to 77°F (20°C to 25°C).Keep Rubraca and all medicines out of the reach of children.
General information about the safe and effective use of Rubraca. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Rubraca for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about Rubraca.
What are the ingredients in Rubraca? Active ingredient:rucaparib Inactive ingredients:microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The film coating contains polyvinyl alcohol, titanium dioxide, polyethylene glycol/macrogol, and talc. The blue film coating contains brilliant blue aluminum lake and indigo carmine aluminum lake. The yellow film coating contains yellow iron oxide. Manufactured for: pharmaand GmbH, Taborstrasse 1, 1020 Wien, AustriaDistributed by: Summit SD LLC, 420 NW Capital Drive, Lee’s Summit, MO 64086For more information call tel: 1-800-506-8501
"],"animal_pharmacology_and_or_toxicology":["Data","Animal Data In a dose range-finding embryo-fetal development study, pregnant rats received oral doses of 50, 150, 500, or 1000 mg/kg/day of rucaparib during the period of organogenesis. Post-implantation loss (100% early resorptions) was observed in all animals at doses greater than or equal to 50 mg/kg/day (with maternal systemic exposures approximately 0.04 times the human exposure at the recommended dose based on AUC 0-24h )."],"package_label_principal_display_panel":["Principal Display Panel - Rubraca tablets 200 mg Bottle Label NDC 82154-0783-1 Rubraca ® (rucaparib) tablets 200 mg* 60 tablets Each tablet contains 344 mg rucaparib camsylate equivalent to 200 mg rucaparib Rx only Keep out of reach of children 200mg","Principal Display Panel - Rubraca tablets 250 mg Bottle Label NDC 82154-0784-1 Rubraca ® (rucaparib) tablets 250 mg* 60 tablets Each tablet contains 430 mg rucaparib camsylate equivalent to 250 mg rucaparib Rx only Keep out of reach of children 250mg","Principal Display Panel - Rubraca tablets 300 mg Bottle Label NDC 82154-0785-1 Rubraca ® (rucaparib) tablets 300 mg* 60 tablets Each tablet contains 516 mg rucaparib camsylate equivalent to 300 mg rucaparib Rx only Keep out of reach of children 300mg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with rucaparib. Rucaparib was clastogenic in an in vitro chromosomal aberration assay in cultured human lymphocytes. The clastogenic response in mitotically-stimulated cells was anticipated based on the mechanism of action of rucaparib and indicates potential genotoxicity in humans. Rucaparib was not mutagenic in a bacterial reverse mutation (Ames) test. Fertility studies with rucaparib have not been conducted. In 3-month repeat-dose general toxicology studies, rucaparib had no effects on male and female reproductive organs at doses up to 100 mg/kg/day and 20 mg/kg/day in rats and dogs, respectively. These dose levels resulted in systemic exposures of approximately 0.3 and 0.09 times the human exposure (AUC 0-24h ), respectively, at the recommended dose."]},"safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"nausea","drugRate":"68%","_validated":true,"placeboRate":""},{"effect":"asthenia/fatigue","drugRate":"65%","_validated":true,"placeboRate":""},{"effect":"anemia/hemoglobin decreased","drugRate":"45%","_validated":true,"placeboRate":""},{"effect":"AST/ALT increased","drugRate":"39%","_validated":true,"placeboRate":""},{"effect":"vomiting","drugRate":"36%","_validated":true,"placeboRate":""},{"effect":"diarrhea","drugRate":"29%","_validated":true,"placeboRate":""},{"effect":"decreased appetite","drugRate":"27%","_validated":true,"placeboRate":""},{"effect":"thrombocytopenia/platelet count decreased","drugRate":"25%","_validated":true,"placeboRate":""},{"effect":"dysgeusia","drugRate":"24%","_validated":true,"placeboRate":""},{"effect":"neutropenia/neutrophil count decreased","drugRate":"21%","_validated":true,"placeboRate":""},{"effect":"blood creatinine increased","drugRate":"17%","_validated":true,"placeboRate":""},{"effect":"dyspnea","drugRate":"16%","_validated":true,"placeboRate":""},{"effect":"dizziness","drugRate":"14%","_validated":true,"placeboRate":""},{"effect":"dyspepsia","drugRate":"11%","_validated":true,"placeboRate":""},{"effect":"photosensitivity reaction","drugRate":"10%","_validated":true,"placeboRate":""},{"effect":"leukopenia/white blood cell count decreased","drugRate":"10%","_validated":true,"placeboRate":""},{"effect":"fatigue/asthenia","drugRate":"61%","_validated":true,"placeboRate":""},{"effect":"musculoskeletal pain","drugRate":"52%","_validated":true,"placeboRate":""},{"effect":"nausea","drugRate":"52%","_validated":true,"placeboRate":""},{"effect":"anemia/decreased hemoglobin","drugRate":"49%","_validated":true,"placeboRate":""},{"effect":"decreased appetite","drugRate":"35%","_validated":true,"placeboRate":""},{"effect":"increased ALT/AST","drugRate":"31%","_validated":true,"placeboRate":""},{"effect":"constipation","drugRate":"30%","_validated":true,"placeboRate":""},{"effect":"diarrhea","drugRate":"27%","_validated":true,"placeboRate":""},{"effect":"vomiting","drugRate":"26%","_validated":true,"placeboRate":""},{"effect":"thrombocytopenia/decreased platelet count","drugRate":"21%","_validated":true,"placeboRate":""},{"effect":"dyspnea","drugRate":"20%","_validated":true,"placeboRate":""},{"effect":"increased blood creatinine","drugRate":"19%","_validated":true,"placeboRate":""},{"effect":"edema","drugRate":"19%","_validated":true,"placeboRate":""},{"effect":"dizziness","drugRate":"19%","_validated":true,"placeboRate":""},{"effect":"weight decreased","drugRate":"16%","_validated":true,"placeboRate":""},{"effect":"abdominal pain","drugRate":"15%","_validated":true,"placeboRate":""},{"effect":"dysgeusia","drugRate":"15%","_validated":true,"placeboRate":""},{"effect":"rash","drugRate":"13%","_validated":true,"placeboRate":""},{"effect":"neuropathy peripheral","drugRate":"13%","_validated":true,"placeboRate":""},{"effect":"urinary tract infection","drugRate":"13%","_validated":true,"placeboRate":""},{"effect":"cough","drugRate":"12%","_validated":true,"placeboRate":""},{"effect":"headache","drugRate":"12%","_validated":true,"placeboRate":""},{"effect":"hemorrhage","drugRate":"12%","_validated":true,"placeboRate":""},{"effect":"neutropenia/decreased neutrophil count","drugRate":"12%","_validated":true,"placeboRate":""},{"effect":"photosensitivity reaction","drugRate":"10%","_validated":true,"placeboRate":""}],"discontinuationRates":[{"trial":"ARIEL3","drugArm":"15%","placeboArm":"5%","commonReason":"thrombocytopenia (4%), nausea (3%), and anemia (2%)"}],"seriousAdverseEvents":[{"event":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","detail":"[see Warnings and Precautions (5.1)]","severity":"serious","incidence":""}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=RUCAPARIB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:20:15.470206+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:20:20.874596+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:20:15.539689+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RUCAPARIB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:20:21.379640+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:14.354438+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:22:01.007498+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:14.354471+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cancer cell death. Increased rucaparib-induced cytotoxicity and anti-tumor activity was observed in tumor cell lines with deficien","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:35.975076+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: PARP 1, 2 and 3 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:20:22.616291+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1173055/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:20:22.269822+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions ( 5.1 )]. Most common adverse reactions (≥10%) among patients with ovarian cancer were nausea, fatigue (including asthenia), anemia, ALT/AST increased, vomiting, diarrhea, decreased appetite, thrombocytopenia, dysgeusia, neutropenia, blood creatinine increased, dyspnea, dizziness, dyspepsia, photosensitivity reaction, a","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:42.554439+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA209115","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:14.354480+00:00"}},"allNames":"rubraca","_dailymed":{"setId":"0295d202-1cfe-7659-e063-6294a90a476e","title":"RUBRACA (RUCAPARIB) TABLET, FILM COATED [PHARMAAND GMBH]"},"mechanism":{"target":"PARP-1, PARP-2, PARP-3","modality":"Small molecule","explanation":"Rucaparib works by blocking PARP enzymes, which are crucial for repairing damaged DNA. This leads to the accumulation of DNA damage in cancer cells, triggering cell death. The effect is more pronounced in cells with defects in other DNA repair mechanisms, such as BRCA1/2 mutations.","oneSentence":"Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies.","technicalDetail":"Rucaparib inhibits the enzymatic activity of PARP-1, PARP-2, and PARP-3, leading to increased formation of PARP-DNA complexes and subsequent DNA damage. This results in apoptosis and cancer cell death, particularly in tumor cell lines with deficiencies in BRCA1/2 and other DNA repair genes."},"_scrapedAt":"2026-03-27T23:37:26.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:22:01.146869+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"rucaparib-maintenance-treatment-of-brca-","name":"Maintenance treatment of BRCA-mutated recurrent ovarian cancer","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy","diagnosticRequired":null,"brandNameForIndication":"Rubraca"},{"id":"rucaparib-treatment-of-brca-mutated-mcrp","name":"Treatment of BRCA-mutated mCRPC","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy","diagnosticRequired":"FDA-approved companion diagnostic for RUBRACA","brandNameForIndication":"Rubraca"}]},"trialDetails":[{"nctId":"NCT03694262","phase":"PHASE2","title":"The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-07-19","conditions":"Endometrial Cancer, Uterine Carcinosarcoma","enrollment":30},{"nctId":"NCT03617679","phase":"PHASE2","title":"Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-03-06","conditions":"Metastatic Endometrial Cancer","enrollment":79},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT04539327","phase":"","title":"Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2020-07-29","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":51},{"nctId":"NCT03559049","phase":"PHASE1, PHASE2","title":"Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2018-12-24","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":25},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":61},{"nctId":"NCT03768063","phase":"PHASE3","title":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-02-28","conditions":"Cancer","enrollment":1000},{"nctId":"NCT03338790","phase":"PHASE2","title":"An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-19","conditions":"Prostate Cancer","enrollment":292},{"nctId":"NCT03542175","phase":"PHASE1","title":"A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-23","conditions":"Breast Cancer","enrollment":31},{"nctId":"NCT04276376","phase":"PHASE2","title":"Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-04-12","conditions":"Solid Tumor","enrollment":130},{"nctId":"NCT04624178","phase":"PHASE2","title":"A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-05","conditions":"Leiomyosarcoma","enrollment":20},{"nctId":"NCT02711137","phase":"PHASE1, PHASE2","title":"Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2016-05-18","conditions":"Solid Tumors","enrollment":137},{"nctId":"NCT06168487","phase":"PHASE1","title":"Telmisartan in Prostate Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2024-04-22","conditions":"Prostate Cancer","enrollment":36},{"nctId":"NCT02975934","phase":"PHASE3","title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-06-13","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":405},{"nctId":"NCT03522246","phase":"PHASE3","title":"A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"pharmaand GmbH","startDate":"2018-05-14","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer","enrollment":1097},{"nctId":"NCT03442556","phase":"PHASE2","title":"Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-08-24","conditions":"ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation","enrollment":18},{"nctId":"NCT02678182","phase":"PHASE2","title":"Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2015-02","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach","enrollment":494},{"nctId":"NCT02873962","phase":"PHASE2","title":"A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-11-10","conditions":"Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer","enrollment":73},{"nctId":"NCT03639935","phase":"PHASE2","title":"Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-03-28","conditions":"Biliary Tract Cancer","enrollment":32},{"nctId":"NCT03845296","phase":"PHASE2","title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2019-04-16","conditions":"Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity","enrollment":64},{"nctId":"NCT04253262","phase":"PHASE1, PHASE2","title":"A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brown University","startDate":"2020-04-03","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":13},{"nctId":"NCT04209595","phase":"PHASE1, PHASE2","title":"PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-08","conditions":"Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas","enrollment":10},{"nctId":"NCT03552471","phase":"PHASE1","title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2018-07-12","conditions":"BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive","enrollment":25},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT04826198","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2020-10-05","conditions":"Ovarian Cancer","enrollment":13},{"nctId":"NCT04227522","phase":"PHASE3","title":"Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients","status":"COMPLETED","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2020-06-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":42},{"nctId":"NCT03958045","phase":"PHASE2","title":"Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Zhonglin Hao","startDate":"2019-09-04","conditions":"Small Cell Lung Cancer","enrollment":33},{"nctId":"NCT03413995","phase":"PHASE2","title":"Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-10","conditions":"Prostate Cancer Metastatic","enrollment":12},{"nctId":"NCT03911453","phase":"EARLY_PHASE1","title":"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2019-04-19","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT01074970","phase":"PHASE2","title":"PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations","status":"COMPLETED","sponsor":"Hoosier Cancer Research Network","startDate":"2010-02","conditions":"Breast Cancer","enrollment":135},{"nctId":"NCT03337087","phase":"PHASE1, PHASE2","title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2018-11-02","conditions":"Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma","enrollment":18},{"nctId":"NCT04676334","phase":"PHASE3","title":"CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2021-03-22","conditions":"Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer","enrollment":34},{"nctId":"NCT03533946","phase":"PHASE2","title":"Rucaparib in Nonmetastatic prOstAte With BRCAness","status":"TERMINATED","sponsor":"University of Utah","startDate":"2019-05-20","conditions":"Prostate Cancer","enrollment":7},{"nctId":"NCT03476798","phase":"PHASE2","title":"Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2018-06-29","conditions":"Cervical Cancer, Endometrial Cancer","enrollment":49},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT03992131","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)","status":"TERMINATED","sponsor":"pharmaand GmbH","startDate":"2019-06-28","conditions":"Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma","enrollment":25},{"nctId":"NCT03840200","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-12","conditions":"Breast Cancer, Prostate Cancer, Ovarian Cancer","enrollment":51},{"nctId":"NCT04171700","phase":"PHASE2","title":"A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes","status":"TERMINATED","sponsor":"pharmaand GmbH","startDate":"2020-01-16","conditions":"Solid Tumor","enrollment":83},{"nctId":"NCT03140670","phase":"PHASE2","title":"Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2017-09-05","conditions":"Pancreatic Cancer","enrollment":46},{"nctId":"NCT04179396","phase":"PHASE1","title":"Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2019-12-05","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":8},{"nctId":"NCT02042378","phase":"PHASE2","title":"A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2014-04","conditions":"Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":19},{"nctId":"NCT01891344","phase":"PHASE2","title":"A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2013-10-30","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":491},{"nctId":"NCT03824704","phase":"PHASE2","title":"A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)","status":"TERMINATED","sponsor":"pharmaand GmbH","startDate":"2019-08-23","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":1},{"nctId":"NCT03499444","phase":"PHASE1","title":"A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2018-02-06","conditions":"Advanced Solid Tumor","enrollment":29},{"nctId":"NCT02740712","phase":"PHASE1","title":"Pharmacokinetic Drug-Drug Interaction Study of Rucaparib","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2016-04","conditions":"Neoplasms","enrollment":17},{"nctId":"NCT01968213","phase":"PHASE3","title":"Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2014-04-07","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":564},{"nctId":"NCT02952534","phase":"PHASE2","title":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-02-15","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":277},{"nctId":"NCT02986100","phase":"PHASE1","title":"Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2016-11","conditions":"Solid Tumor","enrollment":6},{"nctId":"NCT03397394","phase":"PHASE2","title":"Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","status":"TERMINATED","sponsor":"pharmaand GmbH","startDate":"2018-06-01","conditions":"Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":97},{"nctId":"NCT03521037","phase":"PHASE1","title":"Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2018-02-27","conditions":"Neoplasms","enrollment":16},{"nctId":"NCT01482715","phase":"PHASE1, PHASE2","title":"A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2011-11","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":136},{"nctId":"NCT02855944","phase":"PHASE3","title":"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-03-01","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":349},{"nctId":"NCT02935634","phase":"PHASE2","title":"A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11-29","conditions":"Advanced Gastric Cancer","enrollment":190},{"nctId":"NCT03954366","phase":"PHASE1","title":"Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2019-04-25","conditions":"Neoplasms","enrollment":36},{"nctId":"NCT01009190","phase":"PHASE1","title":"A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2010-02","conditions":"Advanced Solid Tumors","enrollment":85},{"nctId":"NCT04774406","phase":"","title":"Arterial Hypertension Related to PARP Inhibitors (ArteRIB)","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-02-24","conditions":"Cancer","enrollment":2336},{"nctId":"NCT03654833","phase":"PHASE2","title":"Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","status":"UNKNOWN","sponsor":"University of Leicester","startDate":"2019-01-28","conditions":"Mesothelioma, Malignant","enrollment":186},{"nctId":"NCT03995017","phase":"PHASE1, PHASE2","title":"Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Kansas Medical Center","startDate":"2020-01-09","conditions":"Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma","enrollment":34},{"nctId":"NCT04774627","phase":"","title":"Pancytopenia Related to PARP Inhibitors (PancytoRIB)","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-02-07","conditions":"Cancer","enrollment":200},{"nctId":"NCT03462212","phase":"PHASE1, PHASE2","title":"Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-03-17","conditions":"Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer","enrollment":290},{"nctId":"NCT02505048","phase":"PHASE2","title":"A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2016-03","conditions":"Metastatic Breast Cancer","enrollment":41},{"nctId":"NCT04326023","phase":"","title":"Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2020-02-09","conditions":"Cancer","enrollment":178},{"nctId":"NCT03572478","phase":"PHASE1, PHASE2","title":"Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2018-08-14","conditions":"Prostate Cancer, Endometrial Cancer","enrollment":12},{"nctId":"NCT03318445","phase":"PHASE1","title":"Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair","status":"COMPLETED","sponsor":"Pamela Munster","startDate":"2018-01-12","conditions":"Solid Tumor, Unspecified, Adult","enrollment":22},{"nctId":"NCT03101280","phase":"PHASE1","title":"A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-04-27","conditions":"Gynecologic Neoplasms","enrollment":29},{"nctId":"NCT03795272","phase":"PHASE2","title":"Rucaparib Maintenance Therapy in Advanced Cervical Cancer","status":"WITHDRAWN","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2019-10-01","conditions":"Cervical Cancer","enrollment":""},{"nctId":"NCT00664781","phase":"PHASE2","title":"Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2007-12","conditions":"brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer","enrollment":78},{"nctId":"NCT00457470","phase":"PHASE2","title":"A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2007-06","conditions":"Diabetes Mellitus, Diabetic Retinopathy","enrollment":""}],"_emaApprovals":[{"name":"Rubraca","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":2503,"reaction":"FATIGUE"},{"count":2227,"reaction":"NAUSEA"},{"count":1166,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":788,"reaction":"DECREASED APPETITE"},{"count":765,"reaction":"CONSTIPATION"},{"count":762,"reaction":"VOMITING"},{"count":761,"reaction":"DIARRHOEA"},{"count":663,"reaction":"ASTHENIA"},{"count":571,"reaction":"ADVERSE EVENT"},{"count":563,"reaction":"CARBOHYDRATE ANTIGEN 125 INCREASED"}],"administration":{"route":"Oral"},"crossReferences":{"chemblId":"CHEMBL1173055"},"_approvalHistory":[{"date":"20200515","type":"SUPPL","sponsor":"PHARMAAND","applicationNumber":"NDA209115"},{"date":"20210930","type":"SUPPL","sponsor":"PHARMAAND","applicationNumber":"NDA209115"},{"date":"20251217","type":"SUPPL","sponsor":"PHARMAAND","applicationNumber":"NDA209115"},{"date":"20221221","type":"SUPPL","sponsor":"PHARMAAND","applicationNumber":"NDA209115"},{"date":"20161219","type":"ORIG","sponsor":"PHARMAAND","applicationNumber":"NDA209115"},{"date":"20220610","type":"SUPPL","sponsor":"PHARMAAND","applicationNumber":"NDA209115"},{"date":"20180406","type":"SUPPL","sponsor":"PHARMAAND","applicationNumber":"NDA209115"},{"date":"20201008","type":"SUPPL","sponsor":"PHARMAAND","applicationNumber":"NDA209115"},{"date":"20251217","type":"SUPPL","sponsor":"PHARMAAND","applicationNumber":"NDA209115"}],"publicationCount":696,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"Rubraca","genericName":"RUCAPARIB","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"2016","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:22:01.146869+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}